<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="chapter-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><?noissn?><front><journal-meta><journal-id journal-id-type="publisher-id">978-3-319-74814-6</journal-id><journal-id journal-id-type="doi">10.1007/978-3-319-74814-6</journal-id><journal-id journal-id-type="nlm-ta">Biomedical Applications of Metals</journal-id><journal-title-group><journal-title>Biomedical Applications of Metals</journal-title></journal-title-group><isbn publication-format="print">978-3-319-74813-9</isbn><isbn publication-format="electronic">978-3-319-74814-6</isbn></journal-meta><article-meta><article-id pub-id-type="pmcid">7122828</article-id><article-id pub-id-type="publisher-id">8</article-id><article-id pub-id-type="doi">10.1007/978-3-319-74814-6_8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Metal-Based Drugs for Treatment of Malaria</article-title></title-group><contrib-group content-type="book editors"><contrib contrib-type="editor"><name><surname>Rai</surname><given-names>Mahendra</given-names></name><address><email>mahendrarai@sgbau.ac.in</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="editor"><name><surname>Ingle</surname><given-names>Avinash P.</given-names></name><address><phone>+919109423848217</phone><email>ingleavinash14@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="editor"><name><surname>Medici</surname><given-names>Serenella</given-names></name><address><email>Sere@uniss.it</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0690 8229</institution-id><institution-id institution-id-type="GRID">grid.444309.e</institution-id><institution>Nanobiotechnology Laboratory, Department of Biotechnology, </institution><institution>Sant Gadge Baba Amravati University, </institution></institution-wrap>Amravati, Maharashtra India </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0690 8229</institution-id><institution-id institution-id-type="GRID">grid.444309.e</institution-id><institution>Nanobiotechnology Laboratory, Department of Biotechnology, </institution><institution>Sant Gadge Baba Amravati University, </institution></institution-wrap>Amravati, Maharashtra India </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2097 9138</institution-id><institution-id institution-id-type="GRID">grid.11450.31</institution-id><institution>Departmento Di Chimica Farmacia, </institution><institution>University of Sassari, </institution></institution-wrap>Sassari, Italy </aff></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Marcelino</surname><given-names>Paulo Ricardo Franco</given-names></name><address><email>paulorfm1@hotmail.com</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Moreira</surname><given-names>Mariete Barbosa</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Lacerda</surname><given-names>Talita Martins</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>da Silva</surname><given-names>Silvio Silv&#x000e9;rio</given-names></name><address><email>ssilverio@gmail.com</email></address><xref ref-type="aff" rid="Aff4"/></contrib><aff id="Aff4"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0722</institution-id><institution-id institution-id-type="GRID">grid.11899.38</institution-id><institution>Department of Biotechnology, Engineering School of Lorena, </institution><institution>S&#x000e3;o Paulo University, </institution></institution-wrap>CEP 12602-810, Lorena, Brazil </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>12</month><year>2017</year></pub-date><fpage>167</fpage><lpage>193</lpage><permissions><copyright-statement>&#x000a9; Springer International Publishing AG 2018</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Despite the incessant efforts to decrease exorbitant number of daily deaths, malaria remains a major threat to the public health in many countries. Transmitted by <italic>Anopheles</italic> mosquitoes, it is caused by infection with <italic>Plasmodium</italic> parasites that have become resistant to many antimalarial drugs. In this context, series of metal-based compounds have been screened for optimal activity against different <italic>Plasmodium</italic> species and strains. This chapter briefly reviews current and potential uses of metal complexes (such as iron, cobalt, nickel, gallium, copper, gold, and silver), metal chelators, and organometallic compounds, as interesting medicinal agents that greatly benefits the fight against malaria.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Malaria</kwd><kwd>Plasmodium</kwd><kwd>Anopheles</kwd><kwd>Metals</kwd><kwd>Drug</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing AG 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">
Malaria is a neglected tropical disease caused by the protozoan of the genus and transmitted by the female (<italic>Culicidae</italic>) mosquitoes (Fran&#x000e7;a et al. <xref ref-type="bibr" rid="CR35">2008</xref>). Probably originated in Africa, malaria has been plaguing the humanity for millennia, which can be inferred from documents of ancient civilizations that preceded the Christian era (Egyptians, Chinese, Mesopotamian, Hindus, Greeks, and Romans). Important figures in the human history, such as Pharaoh Tutankhamun and his family (1324 BC), Saint Augustine (579 BC), Dante Alighieri (1321 AD), and Charles V of the Holy Roman Germanic Empire (1558 AD), were affected by severe intermittent fevers (Celli <xref ref-type="bibr" rid="CR21">1925</xref>; Bruce-Chwatt <xref ref-type="bibr" rid="CR19">1988</xref>; Hawass et al. <xref ref-type="bibr" rid="CR43">2010</xref>; Fiocruz <xref ref-type="bibr" rid="CR32">2017</xref>).</p><p id="Par3">The great navigations and the consequent territorial conquests were the perfect opportunity for malaria to spread to other regions of the planet, being considered one of the most devastating diseases of North American colonies between the XVI and the XVIII centuries (Duffy <xref ref-type="bibr" rid="CR31">1953</xref>; Ackerknecht <xref ref-type="bibr" rid="CR2">1966</xref>; Russell <xref ref-type="bibr" rid="CR78">1968</xref>). At the XVIII century, Italians thought that the symptoms of intermittent fever were due to unhealthy air&#x02014;&#x0201c;<italic>mal aire</italic>&#x0201d;&#x02014;and that expression gave rise to the current name of the disease, malaria. In South America, this disease arrived through the ships that brought the slaves to work mainly in Brazil (Yalcindag et al. <xref ref-type="bibr" rid="CR97">2012</xref>). At the XVII century, as the mortality increased, South American, Indians, and Jesuit priests started using teas and beverages prepared with <italic>Cinchona </italic>sp. as treatment (Lee <xref ref-type="bibr" rid="CR48">2002</xref>; Ockenhouse et al. <xref ref-type="bibr" rid="CR69">2005</xref>). In 1820, Pierre Pelletier and Joseph Caventau isolated quinine from <italic>Cinchona</italic> sp., proved its antimalarial effect, and in the next year, quinine and quinine sulfate were commercially available as the first antimalarial drugs (Cunico et al. <xref ref-type="bibr" rid="CR27">2008</xref>). Despite the discovery of an effective active principle, it took some decades to elucidate the causes of malaria. It was in 1880 that the French physician Charles Alphonse Laveran observed the malaria-causing protozoa in red blood cells of one of his patients. Between 1897 and 1899, Italian researchers Amico Bignami, Giuseppe Bastianelli, Battista Grassi, and the English physician Ronald Ross identified the female of the <italic>Anopheles</italic> mosquito as the transmitter of <italic>Plasmodium</italic> protozoan to the mammals and defined its life cycle, for which he was awarded Nobel Prizes in 1902 and 1907 (Keeble <xref ref-type="bibr" rid="CR45">1997</xref>; Despomnier et al. <xref ref-type="bibr" rid="CR29">2006</xref>; FioCruz <xref ref-type="bibr" rid="CR32">2017</xref>).</p><p id="Par4">Up to the I World War, quinine was the only drug used to treat malaria. The difficulty to obtain the bark of <italic>Cinchona</italic> motivated the Germans to develop, in 1920, a synthetic molecule, 9-aminoacridine, that has been marketed since 1930 by the trade name Atabrine (Wallace <xref ref-type="bibr" rid="CR01">1989</xref>). Despite the advances, the countries involved in the I World War reported large decrease in their populations due to malaria. In the XI Pan American Sanitary Conference in 1942, malaria was identified as the continent&#x02019;s most devastating disease (Rocha et al. <xref ref-type="bibr" rid="CR77">2006</xref>).</p><p id="Par5">In the II World War, also driven by the inherent difficulties for the extraction of quinine from the bark of <italic>Cinchona</italic>, the United States started working in 1942 on an alternative synthetic drug, Atabrine (Curico et al. <xref ref-type="bibr" rid="CR27">2008</xref>). A couple of years later, american researchers in collaboration with pharmaceutical industries attempted to produce a synthetic quinine, but technical drawbacks and the large-scale production costs made this attempt impossible (Lee <xref ref-type="bibr" rid="CR48">2002</xref>).</p><p id="Par6">The failures in the laboratory synthesis of quinine greatly motivated researches for the prospection of new antimalarial drugs such as Amodiaquine, Primaquine, Proguanil, Pyrimethamine, and Chloroquine (Boss et al. <xref ref-type="bibr" rid="CR17">2003</xref>; Ockenhouse et al. <xref ref-type="bibr" rid="CR69">2005</xref>; Silva et al. <xref ref-type="bibr" rid="CR85">2005</xref>). Chloroquine has been highlighted among these drugs due to its efficiency, low production costs, low toxicity, and the possibility of being consumed by pregnant women. These advantages made chloroquine the first choice in the treatment of malaria (Robert et al. <xref ref-type="bibr" rid="CR76">2001</xref>; Silva et al. <xref ref-type="bibr" rid="CR85">2005</xref>).</p><p id="Par7">During the Korean (1950&#x02013;1953) and Vietnam (1950&#x02013;1957) wars, the US Army observed that some malaria patients did not respond to chloroquine. Again, a new drug prospection program was conducted, in which Dapsone, Pyrimethamine, Sulfadoxine, Sulfalene, Mefloquine, and Halofantrine were developed (Boss et al. <xref ref-type="bibr" rid="CR17">2003</xref>; Foley et al. <xref ref-type="bibr" rid="CR33">2005</xref>; Ockenhouse et al. <xref ref-type="bibr" rid="CR69">2005</xref>; Nzila et al. <xref ref-type="bibr" rid="CR68">2006</xref>).</p><p id="Par8">More recently, it was observed that the number of <italic>Plasmodium</italic> strains resistant to the drugs available on the market has increased dramatically, and researches for the discovery of new antimalarial drugs have become increasingly necessary. Some emerging countries like Brazil, India, and China have invested extensively in researches for the treatment of neglected tropical diseases, especially malaria. In the 1970s, Chinese researchers presented artemisinin and its semisynthetic derivatives (Artemether, Arteether, Artesunate, Artemisinic acid, and Dihydroartemisin) as potential antimalarial drugs (Li et al. <xref ref-type="bibr" rid="CR52">1998</xref>; Prince <xref ref-type="bibr" rid="CR72">2000</xref>; Haynes <xref ref-type="bibr" rid="CR44">2001</xref>). The success of these drugs in the treatment of malaria is due to the fact that the <italic>Plasmodium</italic> strains have still little or no resistance to them.</p><p id="Par9">Currently, statistics related to the number of malaria deaths are lower than in previous decades, with a decrease of approximately 52% in the last 15&#x000a0;years (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">8.1</xref>). However, malaria is still present in 108 countries, and in 2015, it was estimated that 212 million people were affected by the disease, with most of the cases concentrated in Southeast Asia, sub-Saharan Africa, and Amazon due to their tropical or subtropical climates that favor the survival and reproduction of <italic>Anopheles</italic> mosquitoes. Also, countries with the highest number of malaria cases are in regions with poor sanitary conditions that also favor the reproduction and development of the malaria vector.<fig id="Fig1"><label>Fig.&#x000a0;8.1</label><caption><p>Number of malaria deaths in the world in the last 15&#x000a0;years (<italic>Source</italic> World Health Organization <xref ref-type="bibr" rid="CR94">2017</xref>)</p></caption><graphic xlink:href="454651_1_En_8_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par10">Projects such as the &#x0201c;Roll Back Malaria Partnership&#x0201d; (RBM) must invest approximately 93 billion euros until 2030 (<ext-link ext-link-type="uri" xlink:href="http://www.rollbackmalaria.org">www.rollbackmalaria.org</ext-link>) for the treatment and total eradication of malaria. However, the success of such initiatives can be compromised once again by problems caused by the resistance of <italic>Plasmodium</italic> lineages. For this reason, research for the development of new antimalarial drugs must be constant. Recently, metal-based drugs have been actively explored for the treatment of a variety of parasites, with an important effect in the treatment of malaria. The following paragraphs aim to present the state-of-the-art of such strategy.</p></sec><sec id="Sec2"><title>General Aspects of Malaria: The Mechanisms of Action of Classic Drugs and the Resistance of the Protozoan</title><p id="Par11">Malaria is a protozoan infection caused by <italic>Plasmodium</italic> (<italic>P. falciparum, P. vivax, P. ovale</italic> and <italic>P. malariae</italic>), with <italic>P. falciparum</italic> being the most dangerous form of the disease due to the related highest rates of complications and mortality. The main vector to humans and other mammals is mosquitoes of the genus <italic>Anopheles</italic>, which comprises more than 400 species, with only a few epidemiologically important. These mosquitoes have nocturnal habits, and only females feed on blood and are responsible for the transmission of the <italic>Plasmodium</italic> (Rabinovitch et al.<xref ref-type="bibr" rid="CR74">1998</xref>; FioCruz <xref ref-type="bibr" rid="CR32">2017</xref>).</p><p id="Par12">The life cycle of the protozoan is divided between a host and an insect vector, as briefly described below and illustrated schematically in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">8.2</xref>. (<bold>I</bold>) By stinging the host, the sporozoite form of <italic>Plasmodium</italic>, lodged in the mosquito&#x02019;s salivary glands, is injected into the bloodstream until it reaches the liver. (<bold>II</bold>) In hepatic cells, the sporozoites reproduce asexually generating other cells called merozoite (not all merozoites reproduce asexually, some develop sexually). (<bold>III</bold>) The merozoites destroy the erythrocytes, causing anemia in the host and initiating a series of reproductive cycles. (<bold>IV</bold>) Some merozoites will become immature gametocytes, precursors of male and female gametes. (<bold>V</bold>) By re-stinging the host, the gametocytes will be collected and matured in the mosquito&#x02019;s digestive system. (<bold>VI</bold>) The fusion of gametocytes will result in zygotes (also named as ookinetes) that will subsequently be converted into sporozoites, which migrate to the salivary glands of the mosquito, thus initiating a new infectious cycle (Rabinovitch et al. <xref ref-type="bibr" rid="CR74">1998</xref>; Cunico et al. <xref ref-type="bibr" rid="CR27">2008</xref>; FioCruz <xref ref-type="bibr" rid="CR32">2017</xref>).<fig id="Fig2"><label>Fig.&#x000a0;8.2</label><caption><p>
<italic>Plasmodium</italic> life cycle. The stages <bold>I</bold>&#x02013;<bold>IV</bold> occur in the host cells and stages <bold>V</bold> and <bold>VI</bold> occur in the <italic>Anopheles</italic> mosquito</p></caption><graphic xlink:href="454651_1_En_8_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par13">The knowledge of the <italic>Plasmodium</italic> life cycle is of fundamental interest in the selection and administration of drugs for the treatment of the infected host. According to Korolkovas and Burckhalter (<xref ref-type="bibr" rid="CR47">1982</xref>), the antimalarials commonly used act on the evolutionary stage of the parasite and can be classified as follows:</p><p id="Par14">
<list list-type="simple"><list-item><label>(I)</label><p id="Par15">Blood schizonticides or suppressive agents: drugs that act on the asexual forms of the parasite found in the bloodstream;</p></list-item><list-item><label>(II)</label><p id="Par16">Tissue schizonticides: drugs that act on the asexual forms of the parasite found in the tissues;</p></list-item><list-item><label>(III)</label><p id="Par17">Gametocytes: drugs that act on the sexual forms of the parasites;</p></list-item><list-item><label>(IV)</label><p id="Par18">Sporonticides: drugs that act indirectly on the vegetative forms found in the mosquito vector through gametocytes;</p></list-item><list-item><label>(V)</label><p id="Par19">Sporozoiticides: drugs that act on the forms of the parasite infecting the host.</p></list-item></list>
</p><p id="Par20">The effects of the above antimalarial drugs on parasite cells are variable according to the infecting species; however, these drugs may act as hemozoin production inhibitors, folic acid synthesis inhibitors, transcription inhibitors or inhibitors of the mitochondrial respiratory chain, transport proteins inhibitors, and genetic material modifiers (Cunico et al. <xref ref-type="bibr" rid="CR27">2008</xref>; Rai et al. <xref ref-type="bibr" rid="CR75">2017</xref>). Table&#x000a0;<xref rid="Tab1" ref-type="table">8.1</xref> shows the main classes of antimalarial used, their molecular structures, and their effects on the parasite.<table-wrap id="Tab1"><label>Table&#x000a0;8.1</label><caption><p>Main classes of antimalarial drugs used in the treatment and their effects on the parasite</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Classes of antimalarial drugs and effects on the parasite</th><th align="left" colspan="2">Main Drugs used on treatment</th></tr></thead><tbody><tr><td align="left" rowspan="5">Aryl-alcohols: hemozoin production inhibitors</td><td align="left">
<bold>Quinine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figa_HTML.gif" id="d29e667"/>
</td></tr><tr><td align="left">
<bold>Mefloquine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figb_HTML.gif" id="d29e680"/>
</td></tr><tr><td align="left">
<bold>Halofantrine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figc_HTML.gif" id="d29e693"/>
</td></tr><tr><td align="left">
<bold>Pyronaridine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figd_HTML.gif" id="d29e706"/>
</td></tr><tr><td align="left">
<bold>Lumefantrine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Fige_HTML.gif" id="d29e719"/>
</td></tr><tr><td align="left" rowspan="6">Artemisinin and derivatives: hemozoin production inhibitors, mitochondrial respiratory chain inhibitors, and transport proteins</td><td align="left">
<bold>Artemisin</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figf_HTML.gif" id="d29e735"/>
</td></tr><tr><td align="left">
<bold>Artemether</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figg_HTML.gif" id="d29e748"/>
</td></tr><tr><td align="left">
<bold>Arteether</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figh_HTML.gif" id="d29e761"/>
</td></tr><tr><td align="left">
<bold>Artesunate</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figi_HTML.gif" id="d29e774"/>
</td></tr><tr><td align="left">
<bold>Artenilic acid</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figj_HTML.gif" id="d29e787"/>
</td></tr><tr><td align="left">
<bold>Dihydroartemisin</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figk_HTML.gif" id="d29e800"/>
</td></tr><tr><td align="left" rowspan="2">Biguanides and derivatives: folic acid synthesis inhibitors</td><td align="left">
<bold>Chloroproguanil</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figl_HTML.gif" id="d29e817"/>
</td></tr><tr><td align="left">
<bold>Cyclochloroproguanil</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figm_HTML.gif" id="d29e830"/>
</td></tr><tr><td align="left" rowspan="2">Naphthoquinones: mitochondrial respiratory chain inhibitors</td><td align="left">
<bold>Atovaquone</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Fign_HTML.gif" id="d29e846"/>
</td></tr><tr><td align="left">
<bold>Ubiquinone</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figo_HTML.gif" id="d29e859"/>
</td></tr><tr><td align="left" rowspan="6">Quinolines: hemozoin production inhibitors and genetic material (DNA) modifiers</td><td align="left">
<bold>Amodiaquine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figp_HTML.gif" id="d29e875"/>
</td></tr><tr><td align="left">
<bold>Primaquine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figq_HTML.gif" id="d29e888"/>
</td></tr><tr><td align="left">
<bold>Chloroquine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figr_HTML.gif" id="d29e901"/>
</td></tr><tr><td align="left">
<bold>Etaquine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figs_HTML.gif" id="d29e914"/>
</td></tr><tr><td align="left">
<bold>Hydroxychloroquine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figt_HTML.gif" id="d29e927"/>
</td></tr><tr><td align="left">
<bold>Plasmoquine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figu_HTML.gif" id="d29e940"/>
</td></tr><tr><td align="left" rowspan="3">Sulfones: inhibitors of folic acid synthesis</td><td align="left">
<bold>Dapsone</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figv_HTML.gif" id="d29e956"/>
</td></tr><tr><td align="left">
<bold>Sulfadoxine</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figw_HTML.gif" id="d29e970"/>
</td></tr><tr><td align="left">
<bold>Sulfalene</bold>
</td><td align="left">
<inline-graphic xlink:href="454651_1_En_8_Figx_HTML.gif" id="d29e983"/>
</td></tr></tbody></table></table-wrap>
</p><p id="Par21">The importance of drugs with the quinoline group (highlighted in bold in the structural formulas of Table&#x000a0;<xref rid="Tab1" ref-type="table">8.1</xref>) is highlighted in several drugs, especially synthetic quinine derivatives that in the last century have achieved significant space in the pharmaceutical market. In addition to the antimalarial effect, recent studies have shown that the active ingredients quinolinics and derivatives presented antiviral activity (antiviral) (Achan et al. <xref ref-type="bibr" rid="CR1">2011</xref>; <ext-link ext-link-type="uri" xlink:href="http://www.cureffi.org">www.cureffi.org</ext-link>).</p><p id="Par22">Despite a variety of drugs used in the treatment of malaria, <italic>Plasmodium</italic> species have become resistant to many compounds. Sibley and Ringwald (<xref ref-type="bibr" rid="CR84">2007</xref>) reported that the emergence of resistance to antimalarial drugs is directly related to an enormous amount of pathogenic populations and the short time of reproduction of the parasite. In addition, the indiscriminate and extensive use of antimalarial drugs also contributes to the process of resistance.</p><p id="Par23">Trying to solve this issue, the World Health Organization (WHO) recommends the use of combinations of antimalaria drugs instead of monotherapy, mainly Artemether/Lumefantrine, Artesunate/Amodiaquine, Artesunate/Mefloquine, Artesunate/Sulfadoxine, and Artesunate/Pyrimethamine (WHO <xref ref-type="bibr" rid="CR95">2007</xref>; Cunico et al. <xref ref-type="bibr" rid="CR27">2008</xref>). Some in vitro studies demonstrated that the compounds verapamil, desipramine, and promethazine may reverse the resistance of <italic>P. falciparum</italic> to chloroquine; however, the mechanisms of this reversal are not yet known (Van Schalkuyk et al. <xref ref-type="bibr" rid="CR88">2001</xref>; Ridley <xref ref-type="bibr" rid="CR03">2002</xref>; Cunico et al. <xref ref-type="bibr" rid="CR27">2008</xref>).</p><p id="Par24">The resistance of the parasites to the classic antimalarial drugs has enormously motivated the prospection of new drugs, and metal-based compounds play an important role in this context. Strategies for the discovery and development of metal-based drugs are driven by the elucidation of the biological profile of the parasite and by the identification of therapeutic targets. Metalloantimalarials are considered very attractive new antimalaria agents as we will see in the following topics.</p></sec><sec id="Sec3"><title>Metalloantimalarials</title><sec id="Sec4"><title>Metal Complexes</title><p id="Par25">The use of metals for therapeutic purposes has following advantages: the possibility of preparing stable complexes with predictable structures, the selective choice of ligands according to their affinity, and the increasing know-how on the metal complexes behavior in biological environments (Allesio <xref ref-type="bibr" rid="CR6">2011</xref>). The antimalarial activities of several metal complexes were already demonstrated, proving their high potential as alternative treatment against resistant <italic>Plasmodium</italic> species (Biot et al. <xref ref-type="bibr" rid="CR14">2012</xref>; Salas et al. <xref ref-type="bibr" rid="CR79">2013</xref>; Wani et al. <xref ref-type="bibr" rid="CR91">2015</xref>).</p></sec><sec id="Sec5"><title>Metal Complexes of Quinoline</title><p id="Par26">
The attachment of a metal atom to an already existent antimalarial drug is an interesting strategy used to enhance its efficacy (Navarro <xref ref-type="bibr" rid="CR63">2009</xref>). Quinoline-containing antimalarial drugs are widely used in malaria therapy, as mentioned in Table&#x000a0;<xref rid="Tab1" ref-type="table">8.1</xref> (Salas et al. <xref ref-type="bibr" rid="CR79">2013</xref>).</p><p id="Par27">Chloroquine (CQ) and aminoquinoline were extensively used for many years (Sharma <xref ref-type="bibr" rid="CR83">2005</xref>; Navarro et al. <xref ref-type="bibr" rid="CR66">2010</xref>). Ruthenium complexes, widely investigated for many applications in medicine, exhibit anticancer, anti-allergic, and antiparasitic potential, as they correspond to nitric oxide donors for vascular relaxation induction (Donnici et al. <xref ref-type="bibr" rid="CR30">2009</xref>; Levina et al. <xref ref-type="bibr" rid="CR51">2009</xref>; Gambino and Otero <xref ref-type="bibr" rid="CR38">2012</xref>; Lima et al. <xref ref-type="bibr" rid="CR53">2014</xref>; Seuanes et al. <xref ref-type="bibr" rid="CR82">2015</xref>; Correa et al. <xref ref-type="bibr" rid="CR25">2016</xref>; Furrer et al. <xref ref-type="bibr" rid="CR37">2016</xref>; Mazuryk et al. <xref ref-type="bibr" rid="CR59">2016</xref>; Zhang et al. <xref ref-type="bibr" rid="CR98">2016</xref>). The synthesis of ruthenium complexes containing CQ as ligands is an interesting strategy to improve the effectiveness of antimalarial drugs (Sanchez-Delgado et al. <xref ref-type="bibr" rid="CR80">1996</xref>; Biot et al. <xref ref-type="bibr" rid="CR13">2011</xref>; Mart&#x000ed;nez et al. <xref ref-type="bibr" rid="CR58">2011</xref>).</p><p id="Par28">Historically, ruthenium CQ complexes were the first class of compounds investigated for this purpose. According to the literature, the binuclear complex of Ru(II) chloroquine [RuCQCl<sub>2</sub>]<sub>2</sub> (<bold>complex 1</bold>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">8.3</xref>) was five times more potent than standard chloroquine against <italic>P. berghei</italic> and <italic>P. falciparum</italic> strains. The mechanism of action of <bold>complex 1</bold> was described as the posthydrolytic binding to hematin in solution inhibiting its aggregation to &#x003b2;-hematin. Results show that the presence of the metal resulted in significantly enhanced activity against CQ-resistant strains (Sanchez-Delgado et al. <xref ref-type="bibr" rid="CR80">1996</xref>; Mart&#x000ed;nez et al. <xref ref-type="bibr" rid="CR57">2008</xref>; Salas et al. <xref ref-type="bibr" rid="CR79">2013</xref>).<fig id="Fig3"><label>Fig.&#x000a0;8.3</label><caption><p>Gold and ruthenium complexes of chloroquine</p></caption><graphic xlink:href="454651_1_En_8_Fig3_HTML" id="MO3"/></fig>
</p><p id="Par29">Sanches-Delgado et al. (<xref ref-type="bibr" rid="CR80">1996</xref>) synthesized the first class of ruthenium complexes containing CQ as ligand. In vitro experiments showed that arena ruthenium complexes were more effective than CQ against resistant strains of <italic>P. falciparum.</italic> Arene-Ru(II)-chloroquine (<bold>complexes 2</bold>&#x02013;<bold>4</bold>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">8.3</xref>) demonstrated appreciable antimalarial activity. Additionally, the interaction between these ruthenium derivatives and target biomolecules was investigated (Mart&#x000ed;nez et al. <xref ref-type="bibr" rid="CR58">2011</xref>).</p><p id="Par30">Another promising class of chloroquine complexes for the development of therapeutic agents are gold complexes (Navarro <xref ref-type="bibr" rid="CR63">2009</xref>; Navarro et al. <xref ref-type="bibr" rid="CR66">2010</xref>). These compounds exhibit antiparasitic potential for the treatment of leishmaniasis, trypanosomiasis, schistosomiasis, and malaria (Fricker et al. <xref ref-type="bibr" rid="CR36">2008</xref>; Navarro <xref ref-type="bibr" rid="CR63">2009</xref>; Vieites et al. <xref ref-type="bibr" rid="CR90">2009</xref>; Navarro et al. <xref ref-type="bibr" rid="CR66">2010</xref>; Biot et al. <xref ref-type="bibr" rid="CR14">2012</xref>).</p><p id="Par31">The antiplasmodial potential of gold complexes was investigated, with a high number of possible ligands that can be coordinated to CQ or chloroquine diphosphate (CQDP), allowing the investigation of antimalarial properties of the several complexes (Navarro <xref ref-type="bibr" rid="CR63">2009</xref>).</p><p id="Par32">In vitro tests showed that the gold complex [Au(PPh<sub>3</sub>)(CQ)]PF<sub>6</sub> (<bold>complex 5</bold>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">8.3</xref>) caused inhibition of two resistant strains of <italic>P. falciparum</italic>, with IC<sub>50</sub> values of 5 and 23&#x000a0;nM, and against a <italic>P. berghei</italic> strain. Studies on the elucidation of the possible mechanism of action of this complex include two targets, i.e., the inhibition of hemozoin (malarial pigment) and DNA interaction. Experiments with mice showed that treatment 1 mg/kg of AuCQ, and parallely with equivalent concentrations of CQDP, induced a reduction in parasite cells of 84 and 44%, respectively, when compared to the untreated control. These results suggest that the complexation of gold to CQ increased the in vivo susceptibility of <italic>P. berghei</italic> to CQ (Navarro et al. <xref ref-type="bibr" rid="CR64">1997</xref>, <xref ref-type="bibr" rid="CR67">2011</xref>) and lead to the search for novel gold&#x02013;CQ complexes, which were synthesized, characterized, and evaluated against CQ-sentitive and CQ-resistant strains of <italic>P. falciparum</italic>. In this perspective, changes in the molecular structure of the [Au(PPh<sub>3</sub>)(CQ)]PF<sub>6</sub> complex were performed, such as variation in the counter anion (<bold>complex 6</bold>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">8.3</xref>), in the phosphine ligand (<bold>complex 7</bold>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">8.3</xref>), and in gold oxidation state (Au (I) and Au (III)) (Navarro et al. <xref ref-type="bibr" rid="CR64">1997</xref>, <xref ref-type="bibr" rid="CR65">2004</xref>).</p><p id="Par33">The literature also reported the antimalarial activities of iron, cobalt, and nickel complexes containing chloroquine (CQ) and Mefloquine (Mef) as ligands. The complexes of general formula [M(II)L<sub>1</sub>L<sub>2</sub>Cl<sub>2</sub>] and [M(III)(Mef)(CQ)Cl<sub>3</sub>)], where L<sub>1</sub>&#x000a0;=&#x000a0;Mefloquine, L<sub>2</sub>&#x000a0;=&#x000a0;chloroquine, M&#x000a0;=&#x000a0;Co<sup>2+</sup>, Ni<sup>2+</sup>, and Fe<sup>3+</sup>, were synthesized, characterized, and evaluated. The in vivo tests revealed that the mixed metal complexes of Mefloquine and chloroquine [Co(Mef)(CQ)Cl<sub>2</sub>] and [Fe(Mef)(CQ)Cl<sub>3</sub>)] exhibited higher antimalarial potential. Furthermore, toxicity studies showed that these complexes demonstrated less toxicity than the Ni(II) analogue (Adediji et al. <xref ref-type="bibr" rid="CR4">2009</xref>). Other quinoline derivatives, Amodiaquine and primaquine, were complexed to several metal ions. The complexes of general formula [M<sup>2+</sup>(Amodiaquine)(Cl)<sub>2</sub>] and [Mn<sup>+</sup>(primaquine)<sub>2</sub>(X)<sub>n</sub>(H<sub>2</sub>O)<sub>y</sub>], where M=&#x000a0;VO(II), Cr(III), Fe(III), Cu(II), Co(II), Ni(II), Zn(II), Cd(II), Hg(II), Rh(III), Pd(II), Au(III), Ag(I), Mn(II), Sn(II), and Pt(II), were prepared and studied as potential antimalarial agents (Wasi et al. <xref ref-type="bibr" rid="CR92">1987</xref>). The antimalarial activity of platinum (II) complexes containing 4-aminoquinoline analogues was also considered (Souza et al. <xref ref-type="bibr" rid="CR86">2011</xref>). All these results indicated that metal complexation to traditional antimalarial quinolones represents an attractive alternative to the development of new antimalarials agents.</p></sec><sec id="Sec6"><title>Metal Complexes of Other Ligands</title><p id="Par34">In a very informative review on gallium(III) complexes as new promising metal-based drug candidates, Lessa et al. (<xref ref-type="bibr" rid="CR50">2012</xref>) mentioned the complex of general formula [Ga-3-Madd]ClO<sub>4</sub>, where H<sub>2</sub>-3-Madd&#x000a0;=&#x000a0;1,12 bis-(2-hydroxy-3-methoxybenzyl)-1,5,8,12-tetraazododecane, active against chloroquine-resistant FCR-3 and Indo-1 lineages at low micromolar concentrations. The complexes [Fe-3-Eadd]ClO<sub>4</sub> (<bold>complex 8</bold>, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">8.4</xref>) and [Ga-3-Eadd]ClO<sub>4</sub> (<bold>complex 9</bold>, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">8.4</xref>), where H<sub>2</sub>-3-Eadd&#x000a0;=&#x000a0;1,12-bis-(2-hydroxy-3-ethyl-benzyl-1,5,8,12-tetraazadodecane, were investigated in respect to their antimalarials activities against HB3 (chloroquine-sensitive) and Dd2 (chloroquine-resistant) <italic>P. falciparum</italic> strains. The results revealed that both complexes were effective against the HB3 chloroquine-resistant strains, but were 10&#x02013;30 times less potent against Dh2 chloroquine-resistant strains. In the case of HB3 strains, both complexes were good inhibitors of hemozoin formation and modest to Dh2 strain. According to the authors, these results suggested that due to the similar antimalarial activities of the complexes, gallium(III) can replace iron(III) in biological environments.<fig id="Fig4"><label>Fig.&#x000a0;8.4</label><caption><p>Chemical structure of some metal complexes with antimalarial activity</p></caption><graphic xlink:href="454651_1_En_8_Fig4_HTML" id="MO4"/></fig>
</p><p id="Par35">The structure&#x02013;activity correlation of some metallic antimalarial complexes was studied. A series of copper (II) complexes containing naphthoquinone ligands were synthesized, characterized, and evaluated. All complexes exhibit enhanced antimalarial activity against 3D7 <italic>P. falciparum</italic> strains. Furthermore, correlations between the antimalarial activity and the metal redox couple indicate the component of the parasitic electron transport chain as a possible target of such compounds (Gokhale et al. <xref ref-type="bibr" rid="CR41">2006</xref>). Complexes containing buparvaquone of general formula [M(II)(L1)<sub>2</sub>(C2H<sub>5</sub>OH)<sub>2</sub>], where M(II)&#x000a0;=&#x000a0;Cu, Co, Ni, Mn, and Fe and L1&#x000a0;=&#x000a0;buparvaquone ({3-trans-(4-tert-butylcyclohexyl) methyl-2-hydroxy-1,4-naphthoquinone}), were studied (Gokhale et al. <xref ref-type="bibr" rid="CR40">2003</xref>). The copper complex that showed better results demonstrated a thousand-fold enhancement in the antimalarial activity of parent quinone against 3D7 strain. Furthermore, this complex was three times more active against the chloroquine-resistant <italic>P. falciparum</italic> K1 strain when compared to the free ligand. Experiments with this strain cellular showed a 90% reduction in parasitemia at a dose of 15&#x000a0;mg/kg, which demonstrates the high potential of the copper complex as antimalarial agent (Gokhale et al. <xref ref-type="bibr" rid="CR40">2003</xref>). The antimalarial activity of gold(I) thiosemicarbazone complexes (<bold>complexes 10</bold> and <bold>11</bold>, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">8.4</xref>) and platinum (II) and palladium(II) complexes with ligands derived from pyrazole (<bold>complexes 12</bold>&#x02013;<bold>15</bold>, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">8.4</xref>) was also investigated. These complexes exhibited better efficacy in comparison to their free ligands against D10, W2, and 3D7 strains of <italic>P. falciparum</italic> (Khanye et al. <xref ref-type="bibr" rid="CR46">2010</xref>; Quirante et al. <xref ref-type="bibr" rid="CR73">2011</xref>). Besides the enhancement of the efficacy of organic drugs, the metal complexes correspond to new alternatives for the treatment of malaria, such as the inhibition of the parasite establishment in the vector mosquito.</p><p id="Par36">Recently, Tapanelli et al. (<xref ref-type="bibr" rid="CR87">2017</xref>) showed that Cu(I), Au(I), and Ag(I) phosphene complexes exhibited notable activity against the <italic>Plasmodium</italic> early sporogonic stages. The results showed that the metal complexes of general formula [M(L)<sub>4</sub>]PF<sub>6</sub> (M&#x000a0;=&#x000a0;Cu(I), Ag(I) and [Au(L)<sub>4</sub>]Cl with L&#x000a0;=&#x000a0;Thp (tris(hydroxymethyl) phosphene) or PTA (1,3,5-triaza-7-phosphaadamantane) interfere with the early sporogonic stage of <italic>Plasmodium,</italic> inhibiting the parasite establishment in the vector mosquito.</p></sec><sec id="Sec7"><title>Metal Chelators</title><p id="Par37">
All microorganisms need iron for their growth and replication (Crumbliss <xref ref-type="bibr" rid="CR26">1990</xref>). Several metabolic processes of the erythrocytic malaria parasite are dependent on iron, such as heme synthesis, DNA synthesis, proteolysis of hemoglobin, glycolysis pentose phosphate shunt, mitochondrial electron transport, and CO<sub>2</sub> fixation. It is therefore an indication that capturing iron from the parasite may interfere negatively on its metabolism (Sharma <xref ref-type="bibr" rid="CR83">2005</xref>).</p><p id="Par38">This strategy corresponds to an interesting alternative for malaria treatment. Common iron-chelating compounds are siderophore, naturally produced by microorganisms to acquire iron from the environment. These compounds can also be administered in the form of free ligands to sequestrate iron, causing the death of the parasite due to deprivation, or in the form of toxic complexes with iron that inhibit parasite growth (Mabeza et al. <xref ref-type="bibr" rid="CR56">1999</xref>).</p><p id="Par39">Some characteristics are very important for effective iron-chelating, such as a hydrophilic&#x02013;hydrophobic balance, the structure of the hex dentate ligand, a selectivity for iron(III), and high affinity for iron and for others cations. The affinity for iron is a main prerequisite for antimalarial activity of an iron-chelating drug, with values of affinity constants iron(III) chelators ranging from 10<sup>24</sup> to 10<sup>38</sup>, according to the literature. The classic chelator desferrioxamine (DFO) (<bold>complex 16</bold>, Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">8.5</xref>), for example, presents an affinity constant value of 10<sup>31</sup>, forming a stable complex with iron and, therefore, a high antimalarial activity. The chelator must have additional affinity for other metals such as calcium, magnesium, and zinc, as their removal may be detrimental for the parasite (Goodwin and Whitten <xref ref-type="bibr" rid="CR42">1965</xref>; Albert <xref ref-type="bibr" rid="CR5">1981</xref>; Lytton et al. <xref ref-type="bibr" rid="CR55">1993</xref>; Ponka et al. <xref ref-type="bibr" rid="CR71">1994</xref>; Cabantchik et al. <xref ref-type="bibr" rid="CR20">1996</xref>).<fig id="Fig5"><label>Fig.&#x000a0;8.5</label><caption><p>Metal chelators used for malaria</p></caption><graphic xlink:href="454651_1_En_8_Fig5_HTML" id="MO5"/></fig>
</p><p id="Par40">The intensity of the antimalarial activity of iron chelators correlates with their hydrophilic/hydrophobic balance, as they can be capable of permeating cell membranes (Scheibel and Rodriguez <xref ref-type="bibr" rid="CR81">1989</xref>). Experimental studies with amino-terminal derivatives of desferrioxamine showed a preserved ability to bind to iron(III) species and a corresponding reduction to bind to iron(II) (Glickstein et al. <xref ref-type="bibr" rid="CR39">1996</xref>). Moreover, iron (III) forms stable complexes with coordination number equal six (Mabeza et al. <xref ref-type="bibr" rid="CR56">1999</xref>).</p><p id="Par41">Desferrioxamine (DFO) is an important representative of iron-chelator and the first example of metal-based drug used to treat malaria. This siderophore occurs naturally in the form of trihydroxamic acid in <italic>Streptomyces pilosus</italic> and is used to treat hemochromatosis. However, the inherent slow permeation into infected cells and the restriction to advanced stages of <italic>P. falciparum</italic> are examples of drawbacks that limit its application (Modell and Berdoukas <xref ref-type="bibr" rid="CR62">1984</xref>; Brittenham <xref ref-type="bibr" rid="CR18">1988</xref>), and some structural modifications were conducted to produce more active and lipophilic derivatives, with broader efficiency for different stages of the infected cells.</p><p id="Par42">As example of this strategy, a more lipophilic complex (MA-DFO, <bold>complex 17</bold>, Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">8.5</xref>) was synthesized by attaching N-methylanthranilic acid to the N-terminus, leading to a higher antimalarial activity. Zinc&#x02013;desferrioxamine (Zn-DFO) complex exhibited increased permeability and improved antimalarial activity when compared to free DFO. A metal substitution reaction occurs inside the erythrocyte, forming the Fe(III)-DFO complex, which is more stable than the Zn-DFO complex (Loyevsky et al.<xref ref-type="bibr" rid="CR54">1993</xref>; Chevion et al.<xref ref-type="bibr" rid="CR24">1995</xref>).</p><p id="Par43">During the last decades, the antimalarial activities of iron-chelating compounds have been investigated and metal chelators such as 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one demonstrated notable ability to inhibit the growth of <italic>P. falciparum</italic> in erythrocytes (Pangjit et al. <xref ref-type="bibr" rid="CR70">2015</xref>). Therefore, iron chelators correspond to a promising area to explore and obtain effective metal-based drugs for malaria.</p></sec><sec id="Sec8"><title>Organometallic Compounds</title><p id="Par44">In organometallic compounds, a metal&#x02013;carbon bond (&#x003c3; or &#x003c0;) provides special features to classic compounds. Many of these complexes have electronic structures based in 18 valence electrons (Miessler and Tarr <xref ref-type="bibr" rid="CR61">2004</xref>) and, due to their use in catalysis and other applications, are considerate potential therapy agents (Chavain and Biot <xref ref-type="bibr" rid="CR23">2010</xref>).</p><p id="Par45">The first organometallic compounds for application in medicine, salvarsan (arsphenamine) and neosalvarsan, were based in arsenic and reported by Paul Ehrlich to treat syphilis and trypanosomiasis (Salas et al. <xref ref-type="bibr" rid="CR79">2013</xref>). Several organometallic complexes were prepared and valued as potential antimalarial agents, with ferrocene exhibiting the hightest antimalarial activity (Wani et al. <xref ref-type="bibr" rid="CR91">2015</xref>). Ferrocenes are highly liposoluble, stable, and nontoxic and have accessible redox potential, which make them very attractive to therapeutic applications (Van-Staveren and Metzler-Nolte <xref ref-type="bibr" rid="CR89">2004</xref>; Fouda et al. <xref ref-type="bibr" rid="CR34">2007</xref>), including malaria treatment. Inspired in ferrocene, several ferrocene-conjugated analogue structures were synthesized such as Mefloquine, artemisia, mepacrine, quinine, atovaquone, and other molecules (Biot et al. <xref ref-type="bibr" rid="CR04">2000</xref>; Blackie et al. <xref ref-type="bibr" rid="CR16">2003</xref>; Blackie and Chibale <xref ref-type="bibr" rid="CR15">2008</xref>).</p><p id="Par46">Until the present moment, ferrochloroquine or ferroquine (FQ) (<bold>complex 18</bold>, Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">8.6</xref>) is the most successful metal-based drug for malaria therapy. This compound was described in 1997 as the first chloroquine derivative containing a ferrocene molecule, incorporating the ferrocene to the lateral side chain of chloroquine (Biot et al. <xref ref-type="bibr" rid="CR9">1997</xref>). Although there are structural similarities between chloroquine and FQ, the in vitro activities against <italic>P. falciparum</italic> of these compounds are distinct. FQ has high efficiency against chloroquine-sensitive and chloroquine-resistant <italic>P. falciparum</italic> parasite strains, reaching efficiencies 20 times higher than chloroquine. FQ exhibited high activity in vivo against <italic>P. yoeli, P. vinckei</italic>, and <italic>P. berghei</italic> strains (Biot et al. <xref ref-type="bibr" rid="CR10">1999</xref>, <xref ref-type="bibr" rid="CR05">2006</xref>).<fig id="Fig6"><label>Fig.&#x000a0;8.6</label><caption><p>Chemical structure of ferroquine (FQ)</p></caption><graphic xlink:href="454651_1_En_8_Fig6_HTML" id="MO6"/></fig>
</p><p id="Par47">Some evidences point that the action of FQ seems to be related to inhibition of the hemozoin formation in the food vacuole of the parasite. Despite the similarity in mechanism when compared to CQ, studies indicated that FQ is more efficient than CQ to inhibit the formation of &#x003b2;-hematin. FQ and CQ showed IC50 values of 0.8 and 1.9, respectively (Biot et al. <xref ref-type="bibr" rid="CR11">2005</xref>).</p><p id="Par48">The ferroquine compound FQ (SSR97193) is a successful representative of an organometallic drug (Sharma <xref ref-type="bibr" rid="CR83">2005</xref>; Biot et al. <xref ref-type="bibr" rid="CR13">2011</xref>). Because of its good antimalarial activity, it has been the object of many studies (Barends et al. <xref ref-type="bibr" rid="CR8">2007</xref>; Biot et al. <xref ref-type="bibr" rid="CR13">2011</xref>; Wani et al. <xref ref-type="bibr" rid="CR91">2015</xref>) and is now the only metal-based compound that is in phase II clinical test for malaria therapy. Daher et al. (<xref ref-type="bibr" rid="CR28">2006</xref>) reported in vitro studies on the metabolism of ferroquine (SSR97193) in animals and humans, indicating potential applications of ferroquine in malaria therapy.</p><p id="Par49">These previous interesting results stimulated the synthesis of several ferroquine derivatives, such as thiosemicarbazones, trioxaferroquines, ferrocene dual conjugates, hydroxyferroquines, and benzothiazoles (Wani et al. <xref ref-type="bibr" rid="CR91">2015</xref>; Adams et al. <xref ref-type="bibr" rid="CR3">2017</xref>). Thiosemicarbazones (TSCs) correspond to a very important class of compound for medicinal chemistry (Leovac et al. <xref ref-type="bibr" rid="CR49">2007</xref>), with interesting biological effects, including antimalarial activity (Bahl et al. <xref ref-type="bibr" rid="CR7">2010</xref>).</p><p id="Par50">In vitro tests against <italic>P. falciparum</italic> strains demonstrated that the antiplasmodial activity of FQ conjugates and thiosemicarbazones was higher than for free thiosemicarbazone. Also, FQ-TSCs (<bold>complex 19</bold>, Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">8.7</xref>) displayed higher efficiency against four <italic>Plasmodium</italic> strains with IC<sub>50</sub> values at micromolar range (Biot et al. <xref ref-type="bibr" rid="CR12">2007</xref>). Hydroxyferroquine derivatives were also tested, and Wani et al. (<xref ref-type="bibr" rid="CR91">2015</xref>) observed that they exhibited antiplasmodial activity and antiviral effects against coronavirus severe acute respiratory syndrome. Hydroxyferroquine (FQ-hydroxy) derivatives (<bold>Complex 20</bold>, Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">8.7</xref>) represent thus an excellent alternative to treat malaria infections caused by coronavirus in some specific geographical regions.<fig id="Fig7"><label>Fig.&#x000a0;8.7</label><caption><p>Derivatives of metal complexes of ferroquine</p></caption><graphic xlink:href="454651_1_En_8_Fig7_HTML" id="MO7"/></fig>
</p><p id="Par51">FQ-trioxaquines (FQ-trioxa) (<bold>Complex 21</bold>, Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">8.7</xref>) are potential antiplasmodial agents. In vitro and in vivo experiments demonstrated that these compounds are highly effective against CQ-resistant strains (Wani et al. <xref ref-type="bibr" rid="CR91">2015</xref>).</p><p id="Par52">Benzothiazoles exhibit appreciable biological activity, and recently, Adams et al. (<xref ref-type="bibr" rid="CR3">2017</xref>) evaluated antimalarial activity of ferrocenyl-containing benzothiazoles (<bold>Complex 22</bold>&#x02013;<bold>24</bold>, Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">8.7</xref>). According to the authors, these compounds presented antiplasmodial activity against CQ-resistant and CQ-sensitive strains. They also observed that ferroquine derivatives were not able to inhibit the formation of &#x003b2;-hematin, indicating that FQ and its derivatives have different mechanisms of action.</p><p id="Par53">The binding of active pharmacophores through covalent linkages is an interesting strategy used for the design of new antimalarial agents, such as ferrocene dual conjugates. The advantage of this strategy is the fact that it causes an increase in the conjugated molecule bioavailability, which diminishes its resistance. Some ferrocene dual conjugates demonstrated good antiplasmodial activities (Meunier <xref ref-type="bibr" rid="CR60">2008</xref>).</p><p id="Par54">The development of ferrocene chemistry led to the investigation of ruthenocene analogues as antimalarial agents. Ruthenoquine (RQ) (<bold>complex 25</bold>, Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8.8</xref>) and its derivatives (<bold>complexes 26</bold> and <bold>27</bold>, Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8.8</xref>) were synthesized and presented good inhibition of <italic>P. falciparum</italic> growth, with similar mechanism of action as FQ (Beagley et al. <xref ref-type="bibr" rid="CR06">2002</xref>). All the results available up to the present moment point to an enormous potential of ferroquine and its derivatives for the development of antiplasmodial agents.<fig id="Fig8"><label>Fig.&#x000a0;8.8</label><caption><p>Ruthenoquine and their derivative compounds</p></caption><graphic xlink:href="454651_1_En_8_Fig8_HTML" id="MO8"/></fig>
</p></sec></sec><sec id="Sec9"><title>Conclusions</title><p id="Par55">The emergence of drug-resistant strains of <italic>Plasmodium</italic> spp. led to an urgent need to develop more effective drugs, and metal-based drugs have been considered a promising strategy against new antiplasmodial agents. In this context, metalloantimalarials based on antimalarial drugs, metal chelators, and organometallic complexes were evaluated. Among all these compounds, ferroquine is the most successful representative, already being tested in phase II clinical trials. Studies on the physiology of the parasite allowed the understanding of the mechanisms of action of new drugs and stimulated the design of new more efficient drugs. With these studies, in the near future, it is expected that metallodrugs with low toxicity and high efficiency will be found for the treatment of neglected tropical diseases such as malaria. In addition, the production costs and the final product are extremely important factors, since this guarantees the accessibility of the population of poor countries affected by these diseases.
</p></sec></body><back><ack><p>The authors thank FAPESP (process number 15/06238-4) and CNPq (process number 304826/2013-8) for the financial support of research carried out in our laboratories.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achan</surname><given-names>J</given-names></name><name><surname>Talisuna</surname><given-names>AO</given-names></name><name><surname>Erhart</surname><given-names>A</given-names></name><name><surname>Yeka</surname><given-names>A</given-names></name><name><surname>Tibenderana</surname><given-names>JK</given-names></name><name><surname>Baliraine</surname><given-names>FN</given-names></name><name><surname>D&#x02019;Alessandro</surname><given-names>U</given-names></name></person-group><article-title>Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria</article-title><source>Malaria J</source><year>2011</year><volume>10</volume><fpage>144</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-10-144</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ackerknecht</surname><given-names>EH</given-names></name></person-group><source>Malaria in the Upper Mississipi Valley, 1760-1900</source><year>1966</year><publisher-loc>Baltimore</publisher-loc><publisher-name>Johns Hopkins Press</publisher-name></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Kock</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>JP</given-names></name><name><surname>Chibale</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>SG</given-names></name></person-group><article-title>Evaluation of ferrocenyl-containing benzothiazoles as potential antiplasmodial agents</article-title><source>Eur J Inorg Chem</source><year>2017</year><volume>2</volume><fpage>242</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1002/ejic.201601000</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adediji</surname><given-names>FJ</given-names></name><name><surname>Olayinka</surname><given-names>TE</given-names></name><name><surname>Adebayo</surname><given-names>AM</given-names></name><name><surname>Babatunde</surname><given-names>O</given-names></name></person-group><article-title>Antimalarial mixed ligand metal complexes: synthesis, physicochemical and biological activities</article-title><source>Int J Phys Sci</source><year>2009</year><volume>9</volume><fpage>529</fpage><lpage>534</lpage></element-citation></ref><ref id="CR5"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>A</given-names></name></person-group><source>Selective toxicity</source><year>1981</year><publisher-loc>New York</publisher-loc><publisher-name>Chapman and Hill</publisher-name></element-citation></ref><ref id="CR6"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Alessio</surname><given-names>E</given-names></name></person-group><source>Bioinorganic medicinal chemistry</source><year>2011</year><publisher-loc>Germany</publisher-loc><publisher-name>Wiley-VCH Velarg &#x00026; Co</publisher-name></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahl</surname><given-names>D</given-names></name><name><surname>Athar</surname><given-names>F</given-names></name><name><surname>Soares</surname><given-names>PBM</given-names></name><name><surname>S&#x000e1;</surname><given-names>SM</given-names></name><name><surname>Moreira</surname><given-names>MRD</given-names></name><name><surname>Srivastava</surname><given-names>MR</given-names></name><name><surname>Leite</surname><given-names>ACL</given-names></name><name><surname>Azam</surname><given-names>A</given-names></name></person-group><article-title>Structure-activity relationship of mononuclear metal-thiosemicabazone complexes endowed with potent antiplasmodial and antiamoebic activities</article-title><source>Bioorg Med Chem</source><year>2010</year><volume>18</volume><fpage>6857</fpage><lpage>6864</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2010.07.039</pub-id><?supplied-pmid 20719524?><pub-id pub-id-type="pmid">20719524</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barends</surname><given-names>M</given-names></name><name><surname>Jaidee</surname><given-names>A</given-names></name><name><surname>Khaohirum</surname><given-names>N</given-names></name><name><surname>Singhasivanon</surname><given-names>P</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name></person-group><article-title>In vitro activity of ferroquine (SSR97193) agaisnt <italic>Plasmodim falciparum</italic> isolates from the Thai-Burmese border</article-title><source>Malaria J</source><year>2007</year><volume>6</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1186/1475-2875-6-81</pub-id></element-citation></ref><ref id="CR06"><mixed-citation publication-type="other">Beagley P, Blackie MAL, Chibale K, Clarkson C, Moss JR, Smith PJ (2002) Synthesis and antimalarial activity in vitro of new ruthenocene-chloroquine analogues. Dalton Trans 23:4426&#x02013;4433</mixed-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biot</surname><given-names>C</given-names></name><name><surname>Glorian</surname><given-names>G</given-names></name><name><surname>Maciejewski</surname><given-names>LA</given-names></name><name><surname>Brocard</surname><given-names>JS</given-names></name><name><surname>Domarle</surname><given-names>O</given-names></name><name><surname>Blampain</surname><given-names>G</given-names></name><etal/></person-group><article-title>Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue</article-title><source>J Med Chem</source><year>1997</year><volume>40</volume><fpage>3715</fpage><lpage>3718</lpage><pub-id pub-id-type="doi">10.1021/jm970401y</pub-id><?supplied-pmid 9371235?><pub-id pub-id-type="pmid">9371235</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biot</surname><given-names>C</given-names></name><name><surname>Delhaes</surname><given-names>L</given-names></name><name><surname>Abessolo</surname><given-names>H</given-names></name><name><surname>Domarle</surname><given-names>O</given-names></name><name><surname>Maciejewski</surname><given-names>LA</given-names></name><name><surname>Mortuaire</surname><given-names>M</given-names></name><name><surname>Delcourt</surname><given-names>P</given-names></name><name><surname>Deloron</surname><given-names>P</given-names></name><name><surname>Camus</surname><given-names>D</given-names></name><name><surname>Dive</surname><given-names>D</given-names></name><name><surname>Brocard</surname><given-names>JS</given-names></name></person-group><article-title>Novel metallocenic compounds as antimalarial agents. Study of the position of ferrocene in chloroquine</article-title><source>J Organomet Chem</source><year>1999</year><volume>589</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/S0022-328X(99)00302-2</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biot</surname><given-names>C</given-names></name><name><surname>Taramelli</surname><given-names>D</given-names></name><name><surname>Forfar-Bares</surname><given-names>I</given-names></name><name><surname>Maciejewski</surname><given-names>L</given-names></name><name><surname>Boyce</surname><given-names>M</given-names></name><name><surname>Nowogrocki</surname><given-names>G</given-names></name><name><surname>Brocard</surname><given-names>JS</given-names></name><name><surname>Basilico</surname><given-names>N</given-names></name><name><surname>Olliaro</surname><given-names>P</given-names></name><name><surname>Egan</surname><given-names>TJ</given-names></name></person-group><article-title>Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity</article-title><source>Mol Pharm</source><year>2005</year><volume>2</volume><fpage>185</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1021/mp0500061</pub-id><?supplied-pmid 15934779?><pub-id pub-id-type="pmid">15934779</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biot</surname><given-names>C</given-names></name><name><surname>Pradines</surname><given-names>B</given-names></name><name><surname>Sergeant</surname><given-names>MH</given-names></name><name><surname>Gut</surname><given-names>J</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name><name><surname>Chibale</surname><given-names>K</given-names></name></person-group><article-title>Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues</article-title><source>Bioorg Med Chem Lett</source><year>2007</year><volume>17</volume><fpage>6434</fpage><lpage>6438</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2007.10.003</pub-id><?supplied-pmid 17949976?><pub-id pub-id-type="pmid">17949976</pub-id></element-citation></ref><ref id="CR96"><mixed-citation publication-type="other">Biot C, Delhaes L, Maclejewski AL (2000) Synthetic ferrocene mefloquine and quinine analogues as potential antimalarial agents. Eur J Med Chem 35: 7&#x02013;8
</mixed-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biot</surname><given-names>C</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Fraisse</surname><given-names>L</given-names></name><name><surname>Ter-minassian</surname><given-names>D</given-names></name><name><surname>Khalife</surname><given-names>J</given-names></name><name><surname>Dive</surname><given-names>D</given-names></name></person-group><article-title>The antimalarial ferroquine: from bench to clinic</article-title><source>Parasite</source><year>2011</year><volume>18</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1051/parasite/2011183207</pub-id><?supplied-pmid 21894260?><pub-id pub-id-type="pmid">21894260</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biot</surname><given-names>C</given-names></name><name><surname>Castro</surname><given-names>W</given-names></name><name><surname>Bott&#x000e9;</surname><given-names>YC</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name></person-group><article-title>The therapeutic potential of metal-based antimalarial agents: implications for the mechanism of action</article-title><source>Dalton Trans</source><year>2012</year><volume>21</volume><fpage>6321</fpage><lpage>6580</lpage></element-citation></ref><ref id="CR04"><mixed-citation publication-type="other">Biot C, Delhaes L, Maclejewski AL, Mortuaire M, Camus D, Dive D, Brocard S J (2000) Synthetic ferrocenic mefloquine and quinine analogues as potential antimalarial agentes. Eur J Med Chem 35:707&#x02013;714</mixed-citation></ref><ref id="CR05"><mixed-citation publication-type="other">Biot C, Daher W, Ndiaye C M, Melnyk P, Pradines B, Chavain N, Pellet A, Fraisse L, Pelinski L, Jarry C, Brocard J, Khalife J, Forfar-Bares I, Dive D (2006) Probing the role of the covalent linkage of ferrocene into a chloroquine template. J Med Chem 49:4707&#x02013;4714</mixed-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackie</surname><given-names>ALM</given-names></name><name><surname>Chibale</surname><given-names>K</given-names></name></person-group><article-title>Metallocene antimalarials: the continuing quest</article-title><source>Metals Based Drug</source><year>2008</year><volume>1</volume><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackie</surname><given-names>ALM</given-names></name><name><surname>Beagley</surname><given-names>CK</given-names></name><name><surname>Clarkson</surname><given-names>C</given-names></name><name><surname>Hutton</surname><given-names>TA</given-names></name><name><surname>Moss</surname><given-names>RJ</given-names></name><name><surname>Smith</surname><given-names>JP</given-names></name></person-group><article-title>Synthesis and antimalarial activity in vitro of new heterobimetallic complexes: Rh and Au derivatives of chloroquine and a series of ferrocenyl-4-amino-7-chloroquines and a series of ferroceny-4-amino-7-chloroquines</article-title><source>J Organomet Chem</source><year>2003</year><volume>688</volume><fpage>144</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.jorganchem.2003.07.026</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boss</surname><given-names>C</given-names></name><name><surname>Richard-Bildstein</surname><given-names>S</given-names></name><name><surname>Weller</surname><given-names>T</given-names></name><name><surname>Fischli</surname><given-names>W</given-names></name><name><surname>Meyer</surname><given-names>S</given-names></name><name><surname>Binkert</surname><given-names>C</given-names></name></person-group><article-title>Inhibitors of the <italic>Plasmodium falciparum</italic> parasite aspartic protease plasmepsin II as potential antimalarial agents</article-title><source>Curr Med Chem</source><year>2003</year><volume>10</volume><fpage>883</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.2174/0929867033457674</pub-id><?supplied-pmid 12678679?><pub-id pub-id-type="pmid">12678679</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brittenham</surname><given-names>GM</given-names></name></person-group><article-title>Iron chelating agentes</article-title><source>Curr Ther Hematol Oncol</source><year>1988</year><volume>3</volume><fpage>149</fpage><lpage>153</lpage></element-citation></ref><ref id="CR19"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bruce-Chwatt</surname><given-names>LJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Wernsdorfer</surname><given-names>WH</given-names></name><name><surname>McGregor</surname><given-names>I</given-names></name></person-group><article-title>History of malaria from prehistory to eradication</article-title><source>Malaria: principles and practice of malariology</source><year>1988</year><publisher-loc>Edinburgh</publisher-loc><publisher-name>Churchill Livingstone</publisher-name><fpage>1</fpage><lpage>59</lpage></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabantchik</surname><given-names>ZI</given-names></name><name><surname>Glickstein</surname><given-names>H</given-names></name><name><surname>Golenser</surname><given-names>J</given-names></name><name><surname>Loyevsky</surname><given-names>M</given-names></name><name><surname>Tsafack</surname><given-names>A</given-names></name></person-group><article-title>Iron chelators: mode of action as antimalarials</article-title><source>Acta Haematol</source><year>1996</year><volume>95</volume><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1159/000203952</pub-id><?supplied-pmid 8604590?><pub-id pub-id-type="pmid">8604590</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>A</given-names></name></person-group><source><italic>Storia della malaria nell&#x02019;agro romano</italic></source><year>1925</year><publisher-loc>Academia dei Lincei</publisher-loc><publisher-name>Roma</publisher-name></element-citation></ref><ref id="CR22"><mixed-citation publication-type="other">Centers for Disease Control and Prevention (2006) Malaria: topic home. In: <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/malaria/">http://www.cdc.gov/malaria/</ext-link></mixed-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavain</surname><given-names>N</given-names></name><name><surname>Biot</surname><given-names>C</given-names></name></person-group><article-title>Organometallic complexes: new tools for chemotherapy</article-title><source>Curr Med Chem</source><year>2010</year><volume>17</volume><fpage>2729</fpage><lpage>2745</lpage><pub-id pub-id-type="doi">10.2174/092986710791859306</pub-id><?supplied-pmid 20586720?><pub-id pub-id-type="pmid">20586720</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chevion</surname><given-names>M</given-names></name><name><surname>Chuang</surname><given-names>L</given-names></name><name><surname>Golenser</surname><given-names>J</given-names></name></person-group><article-title>Effects of zinc-desferrioxamine on <italic>Plasmodium falciparum</italic> in culture</article-title><source>Antimicrob Agents Chemother</source><year>1995</year><volume>39</volume><fpage>1902</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.1128/AAC.39.8.1902</pub-id><?supplied-pmid 7486946?><pub-id pub-id-type="pmid">7486946</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>SR</given-names></name><name><surname>Silva</surname><given-names>MM</given-names></name><name><surname>Graminha</surname><given-names>EA</given-names></name><name><surname>Meira</surname><given-names>SC</given-names></name><name><surname>Santos</surname><given-names>FAJ</given-names></name><name><surname>Moreira</surname><given-names>MRD</given-names></name><name><surname>Soares</surname><given-names>PBM</given-names></name><name><surname>Poelhsitz</surname><given-names>VG</given-names></name><name><surname>Castellano</surname><given-names>EE</given-names></name><name><surname>Bloch</surname><given-names>C</given-names><suffix>Jr</suffix></name><name><surname>Batista</surname><given-names>RM</given-names></name><name><surname>Cominetti</surname><given-names>AA</given-names></name></person-group><article-title>Ruthenium (II) complexes of 1,3-thiazolidine-2-thione: cytotoxicity against tumor cells and anti-<italic>Trypanosoma cruzi</italic> activity enhanced upon combination with benzidazole</article-title><source>J Inorg Biochem</source><year>2016</year><volume>156</volume><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2015.12.024</pub-id><?supplied-pmid 26795676?><pub-id pub-id-type="pmid">26795676</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crumbliss</surname><given-names>AL</given-names></name></person-group><article-title>Iron bioavailability and the coordination chemistry of hydroxamic acids</article-title><source>Coord Chem Rev</source><year>1990</year><volume>105</volume><fpage>155</fpage><pub-id pub-id-type="doi">10.1016/0010-8545(90)80021-K</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunico</surname><given-names>W</given-names></name><name><surname>Carvalho</surname><given-names>AS</given-names></name><name><surname>Gomes</surname><given-names>CRB</given-names></name><name><surname>Marques</surname><given-names>GH</given-names></name></person-group><article-title>F&#x000e1;rmacos antimalariais&#x02014;hist&#x000f3;ria e perspectives</article-title><source>Revista Brasileira de Farm&#x000e1;cia</source><year>2008</year><volume>89</volume><fpage>49</fpage><lpage>55</lpage></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daher</surname><given-names>W</given-names></name><name><surname>Pelinski</surname><given-names>L</given-names></name><name><surname>Klieber</surname><given-names>S</given-names></name><name><surname>Sadoun</surname><given-names>F</given-names></name><name><surname>Meunier</surname><given-names>V</given-names></name><name><surname>Bourri</surname><given-names>M</given-names></name><name><surname>Biot</surname><given-names>C</given-names></name><name><surname>Guilou</surname><given-names>F</given-names></name><name><surname>Fabre</surname><given-names>G</given-names></name><name><surname>Brocard</surname><given-names>J</given-names></name><name><surname>Fraisse</surname><given-names>L</given-names></name><name><surname>Maffrand</surname><given-names>J</given-names></name><name><surname>Khalife</surname><given-names>J</given-names></name><name><surname>Dive</surname><given-names>D</given-names></name></person-group><article-title><italic>In vitro</italic> metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on <italic>Plasmodium falciparum</italic></article-title><source>Drug Metab Dispos</source><year>2006</year><volume>34</volume><fpage>667</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1124/dmd.104.003202</pub-id><?supplied-pmid 16415117?><pub-id pub-id-type="pmid">16415117</pub-id></element-citation></ref><ref id="CR29"><mixed-citation publication-type="other">Despomnier DD, Gwadz RW and Hotez PJ (2006) Parasitic diseases 5th In: <ext-link ext-link-type="uri" xlink:href="http://www.medicalecology.org/pdf/pd_malaria.pdf">http://www.medicalecology.org/pdf/pd_malaria.pdf</ext-link></mixed-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnici</surname><given-names>LC</given-names></name><name><surname>Araujo</surname><given-names>HM</given-names></name><name><surname>Oliveira</surname><given-names>SH</given-names></name><name><surname>Moreira</surname><given-names>MRD</given-names></name><name><surname>Pereira</surname><given-names>ARV</given-names></name><name><surname>Souza</surname><given-names>AM</given-names></name><name><surname>Castro</surname><given-names>BACM</given-names></name><name><surname>Leite</surname><given-names>LCA</given-names></name></person-group><article-title>Ruthenium complexes endowed with potent anti-<italic>Trypanosoma cruzi</italic> activity: synthesis, biological characterization and structure-activity relationships</article-title><source>Bioorg Med Chem</source><year>2009</year><volume>17</volume><fpage>5038</fpage><lpage>5043</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2009.05.071</pub-id><?supplied-pmid 19539479?><pub-id pub-id-type="pmid">19539479</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>J</given-names></name></person-group><source>Epidemics in Colonial Am&#x000e9;rica</source><year>1953</year><publisher-loc>Baton Rouge</publisher-loc><publisher-name>Lousiana State University Press</publisher-name></element-citation></ref><ref id="CR32"><mixed-citation publication-type="other">FioCruz&#x02014;Malaria (2017) In: <ext-link ext-link-type="uri" xlink:href="http://www.cpqrr.fiocruz.br/informacao_em_saude/CICT/malaria/">http://www.cpqrr.fiocruz.br/informacao_em_saude/CICT/malaria/</ext-link> malaria.htm</mixed-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>M</given-names></name><name><surname>Tilley</surname><given-names>L</given-names></name></person-group><article-title>Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents</article-title><source>Pharmacol Ther</source><year>1998</year><volume>79</volume><fpage>55</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/S0163-7258(98)00012-6</pub-id><?supplied-pmid 9719345?><pub-id pub-id-type="pmid">9719345</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fouda</surname><given-names>MFR</given-names></name><name><surname>Abd-Elzaher</surname><given-names>MM</given-names></name><name><surname>Abdelsamaia</surname><given-names>RA</given-names></name><name><surname>Labib</surname><given-names>AA</given-names></name></person-group><article-title>On the medicinal chemistry of ferrocene</article-title><source>Appl Organomet Chem</source><year>2007</year><volume>21</volume><fpage>613</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1002/aoc.1202</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fran&#x000e7;a</surname><given-names>TCC</given-names></name><name><surname>Santos</surname><given-names>MG</given-names></name><name><surname>Figueroa-Villar</surname><given-names>JD</given-names></name></person-group><article-title>Mal&#x000e1;ria: aspectos hist&#x000f3;ricos e quimioterapia</article-title><source>Quim Nova</source><year>2008</year><volume>5</volume><fpage>1271</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1590/S0100-40422008000500060</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fricker</surname><given-names>PS</given-names></name><name><surname>Mosi</surname><given-names>MR</given-names></name><name><surname>Cameron</surname><given-names>RB</given-names></name><name><surname>Baird</surname><given-names>I</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Anastassov</surname><given-names>V</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Doyle</surname><given-names>SP</given-names></name><name><surname>Hansell</surname><given-names>E</given-names></name><name><surname>Lau</surname><given-names>G</given-names></name><name><surname>Langille</surname><given-names>J</given-names></name><name><surname>Olsen</surname><given-names>M</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Skerlj</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>RSY</given-names></name><name><surname>Santucci</surname><given-names>Z</given-names></name><name><surname>Mckerrow</surname><given-names>HJ</given-names></name></person-group><article-title>Metal compounds for the treatment of parasitic diseases</article-title><source>J Inorg Biochem</source><year>2008</year><volume>102</volume><fpage>1839</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2008.05.010</pub-id><?supplied-pmid 18684510?><pub-id pub-id-type="pmid">18684510</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furrer</surname><given-names>J</given-names></name><name><surname>S&#x000fc;ss-Fink</surname><given-names>G</given-names></name></person-group><article-title>Thiolato-bridged dinuclear arene rutheium complexes and their potential as anticaner drug</article-title><source>Coordination Chem</source><year>2016</year><volume>309</volume><fpage>36</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2015.10.007</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gambino</surname><given-names>D</given-names></name><name><surname>Otero</surname><given-names>L</given-names></name></person-group><article-title>Perspectives on what ruthenium-based compounds could offer in the development of potential antiparasitic drugs</article-title><source>Inorg Chim Acta</source><year>2012</year><volume>393</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.ica.2012.05.028</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glickstein</surname><given-names>H</given-names></name><name><surname>Breuer</surname><given-names>B</given-names></name><name><surname>Loyevsky</surname><given-names>M</given-names></name><name><surname>Konijn</surname><given-names>A</given-names></name><name><surname>Libman</surname><given-names>J</given-names></name><name><surname>Shanzer</surname><given-names>A</given-names></name><name><surname>Cabantchik</surname><given-names>ZI</given-names></name></person-group><article-title>Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells</article-title><source>Blood</source><year>1996</year><volume>87</volume><fpage>4871</fpage><lpage>4878</lpage><?supplied-pmid 8639861?><pub-id pub-id-type="pmid">8639861</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gokhale</surname><given-names>HN</given-names></name><name><surname>Padhye</surname><given-names>BS</given-names></name><name><surname>Croft</surname><given-names>LS</given-names></name><name><surname>Kendrick</surname><given-names>DH</given-names></name><name><surname>Davies</surname><given-names>W</given-names></name><name><surname>Anson</surname><given-names>EC</given-names></name><name><surname>Powell</surname><given-names>KA</given-names></name></person-group><article-title>Transition metal complexes of buparvaquone as potent new antimalarial agents Synthesis, X-ray crystal-structures, electrochemistry and antimalarial activity against <italic>Plasmodium falciparum</italic></article-title><source>J Inorg Biochem</source><year>2003</year><volume>95</volume><fpage>249</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/S0162-0134(03)00134-X</pub-id><?supplied-pmid 12818795?><pub-id pub-id-type="pmid">12818795</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gokhale</surname><given-names>HN</given-names></name><name><surname>Shirisha</surname><given-names>K</given-names></name><name><surname>Padhye</surname><given-names>BS</given-names></name><name><surname>Croft</surname><given-names>LS</given-names></name><name><surname>Kendrick</surname><given-names>DH</given-names></name><name><surname>Mckee</surname><given-names>V</given-names></name></person-group><article-title>Metalloantimalarials: Synthesis, x-ray Crystal structure of potent antimalarial copper(II) complex of arylazo-4-hydroxy-1,2-naphthoquinone</article-title><source>Bioorg Med Chem Lett</source><year>2006</year><volume>16</volume><fpage>430</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2005.09.061</pub-id><?supplied-pmid 16275074?><pub-id pub-id-type="pmid">16275074</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>JF</given-names></name><name><surname>Whitten</surname><given-names>CF</given-names></name></person-group><article-title>Chelation of ferrous sulfate solutions by desferrioxamine B</article-title><source>Nature</source><year>1965</year><volume>205</volume><fpage>281</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1038/205281b0</pub-id><?supplied-pmid 14270711?><pub-id pub-id-type="pmid">14270711</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawass</surname><given-names>Z</given-names></name><name><surname>Gad</surname><given-names>YZ</given-names></name><name><surname>Ismail</surname><given-names>S</given-names></name><name><surname>Khairat</surname><given-names>R</given-names></name><name><surname>Fathalla</surname><given-names>D</given-names></name><name><surname>Hasan</surname><given-names>N</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Elleithy</surname><given-names>H</given-names></name><name><surname>Ball</surname><given-names>M</given-names></name><name><surname>Gaballah</surname><given-names>F</given-names></name><name><surname>Wasef</surname><given-names>S</given-names></name><name><surname>Fateen</surname><given-names>M</given-names></name><name><surname>Amer</surname><given-names>H</given-names></name><name><surname>Gostner</surname><given-names>P</given-names></name><name><surname>Selim</surname><given-names>A</given-names></name><name><surname>Zink</surname><given-names>A</given-names></name><name><surname>Pusch</surname><given-names>CM</given-names></name></person-group><article-title>Ancestry and pathology in King Tutankhamun&#x02019;s family</article-title><source>JAMA</source><year>2010</year><volume>7</volume><fpage>638</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.121</pub-id></element-citation></ref><ref id="CR44"><mixed-citation publication-type="other">Haynes R (2001) Artemisia and derivatives: the future of malaria treatment. Curr Opin Inf Dis 14:719&#x02013;726. <ext-link ext-link-type="uri" xlink:href="http://rollbackmalaria.org">http://rollbackmalaria.org</ext-link>. Accessed on 25 Nov 2017</mixed-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keeble</surname><given-names>TW</given-names></name></person-group><article-title>A cure for the ague: the contribuition of Robert Talbor (1642&#x02013;81)</article-title><source>J R Soc Med</source><year>1997</year><volume>90</volume><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1177/014107689709000517</pub-id><?supplied-pmid 9204030?><pub-id pub-id-type="pmid">9204030</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanye</surname><given-names>DS</given-names></name><name><surname>Smith</surname><given-names>SG</given-names></name><name><surname>Lategan</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>JP</given-names></name><name><surname>Gut</surname><given-names>J</given-names></name><name><surname>Rosenthal</surname><given-names>JP</given-names></name><name><surname>Chibale</surname><given-names>K</given-names></name></person-group><article-title>Synthesis and <italic>in vitro</italic> evaluation of gold(I) thiosemicarbazone complexes for antimalarial activity</article-title><source>J Inorg Biochem</source><year>2010</year><volume>104</volume><fpage>1079</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2010.06.005</pub-id><?supplied-pmid 20621360?><pub-id pub-id-type="pmid">20621360</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Korolkovas</surname><given-names>A</given-names></name><name><surname>Burckhalter</surname><given-names>JH</given-names></name></person-group><source>Qu&#x000ed;mica Farmac&#x000ea;utica</source><year>1982</year><publisher-loc>Guanabara Dois</publisher-loc><publisher-name>S&#x000e3;o Paulo</publisher-name></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MR</given-names></name></person-group><article-title>Plants against malaria Part 1: Chinchona or Peruvian Bark</article-title><source>J Roy Coll Phys Edinburg</source><year>2002</year><volume>32</volume><fpage>189</fpage><lpage>196</lpage></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leovac</surname><given-names>MV</given-names></name><name><surname>Jovanovic</surname><given-names>SL</given-names></name><name><surname>Jevtovic</surname><given-names>SV</given-names></name><name><surname>Pelosi</surname><given-names>G</given-names></name><name><surname>Bisceglie</surname><given-names>F</given-names></name></person-group><article-title>Transition metal complexes with thiiosemicarbazide-based ligand&#x02014;Part LV: Synthesis and X-ray structural study of novel Ni(II) complexes with pyridoxal semicarbazone and pyridoxal thiosemicabazone</article-title><source>Polyhedron</source><year>2007</year><volume>26</volume><fpage>2971</fpage><lpage>2978</lpage><pub-id pub-id-type="doi">10.1016/j.poly.2007.01.041</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lessa</surname><given-names>AJ</given-names></name><name><surname>Parrilha</surname><given-names>LG</given-names></name><name><surname>Beraldo</surname><given-names>H</given-names></name></person-group><article-title>Gallium complexes as new promising metallodrugs candidates</article-title><source>Inorg Chim Acta</source><year>2012</year><volume>393</volume><fpage>53</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.ica.2012.06.003</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levina</surname><given-names>A</given-names></name><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>Lay</surname><given-names>AP</given-names></name></person-group><article-title>Recent developments in ruthenium anticancer drugs</article-title><source>Metallomics</source><year>2009</year><volume>1</volume><fpage>458</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1039/b904071d</pub-id><?supplied-pmid 21305154?><pub-id pub-id-type="pmid">21305154</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name></person-group><article-title>How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives?</article-title><source>Med Tropicale (Mars)</source><year>1998</year><volume>58</volume><issue>3 Suppl</issue><fpage>9</fpage><lpage>12</lpage></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>GR</given-names></name><name><surname>Rodrigues</surname><given-names>SRB</given-names></name><name><surname>Silva</surname><given-names>SR</given-names></name><name><surname>Bendhack</surname><given-names>ML</given-names></name></person-group><article-title>Ruthenium complexes as no donors for vascular relaxation induction</article-title><source>Molecules</source><year>2014</year><volume>19</volume><fpage>9628</fpage><lpage>9654</lpage><pub-id pub-id-type="doi">10.3390/molecules19079628</pub-id><?supplied-pmid 25004072?><pub-id pub-id-type="pmid">25004072</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loyevsky</surname><given-names>M</given-names></name><name><surname>Lytton</surname><given-names>SD</given-names></name><name><surname>Mester</surname><given-names>B</given-names></name><name><surname>Libman</surname><given-names>J</given-names></name><name><surname>Shanzer</surname><given-names>A</given-names></name><name><surname>Cabantchik</surname><given-names>ZIJ</given-names></name></person-group><article-title>The Antimalarial action of deferral involves a direct access route to erythrocytic (<italic>Plasmodium falciparum</italic>) parasites</article-title><source>Clin Inv</source><year>1993</year><volume>91</volume><fpage>218</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1172/JCI116174</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lytton</surname><given-names>SD</given-names></name><name><surname>Mester</surname><given-names>B</given-names></name><name><surname>Dayan</surname><given-names>I</given-names></name><name><surname>Glickstein</surname><given-names>H</given-names></name><name><surname>Libman</surname><given-names>J</given-names></name><name><surname>Shanzer</surname><given-names>A</given-names></name><name><surname>Cabantchik</surname><given-names>ZI</given-names></name></person-group><article-title>Mode of action of iron (III) chelators as antimalarials: I. Membrane permeation properties and cytotoxic activity</article-title><source>Blood</source><year>1993</year><volume>81</volume><fpage>214</fpage><lpage>221</lpage><?supplied-pmid 8417790?><pub-id pub-id-type="pmid">8417790</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabeza</surname><given-names>FG</given-names></name><name><surname>Loyevsky</surname><given-names>M</given-names></name><name><surname>Victor</surname><given-names>R</given-names></name><name><surname>Gordeuk</surname><given-names>RV</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name></person-group><article-title>Iron chelation therapy for malaria: a review</article-title><source>Pharmacol Ther</source><year>1999</year><volume>81</volume><fpage>53</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/S0163-7258(98)00037-0</pub-id><?supplied-pmid 10051178?><pub-id pub-id-type="pmid">10051178</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez</surname><given-names>A</given-names></name><name><surname>Rajapakse</surname><given-names>CSK</given-names></name><name><surname>Naoulou</surname><given-names>B</given-names></name><name><surname>Kopkalli</surname><given-names>Y</given-names></name><name><surname>Davenport</surname><given-names>L</given-names></name><name><surname>S&#x000e1;nchez-Delgado</surname><given-names>RA</given-names></name></person-group><article-title>The mechanism of antimalarial action of the ruthenium(II)-chloroquine complex [RuCl<sub>2</sub>(CQ)]<sub>2</sub></article-title><source>J Biol Inorg Chem</source><year>2008</year><volume>13</volume><fpage>703</fpage><pub-id pub-id-type="doi">10.1007/s00775-008-0356-9</pub-id><?supplied-pmid 18305967?><pub-id pub-id-type="pmid">18305967</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez</surname><given-names>A</given-names></name><name><surname>Su&#x000e1;rez</surname><given-names>J</given-names></name><name><surname>Shand</surname><given-names>T</given-names></name><name><surname>Magliozzo</surname><given-names>SR</given-names></name><name><surname>S&#x000e1;nchez-Delgado</surname><given-names>AR</given-names></name></person-group><article-title>Interactions of arene-Ru(II)-chloroquine complexes of know antimalarial and antitumor activity with human s&#x000e9;rum albumin (HSA) and transferrin</article-title><source>J Inorg Biochem</source><year>2011</year><volume>105</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2010.09.005</pub-id><?supplied-pmid 21113330?><pub-id pub-id-type="pmid">21113330</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazuryk</surname><given-names>O</given-names></name><name><surname>Lomzik</surname><given-names>M</given-names></name><name><surname>Martineau</surname><given-names>D</given-names></name><name><surname>Beley</surname><given-names>M</given-names></name><name><surname>Brendell</surname><given-names>M</given-names></name><name><surname>Stochel</surname><given-names>G</given-names></name><name><surname>Gros</surname><given-names>CP</given-names></name></person-group><article-title>Anticancer activity of ruthenium(II) polypyridine complexes bearing pyrrolidine substituents</article-title><source>Inorg Chimica Acta</source><year>2016</year><volume>443</volume><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.ica.2015.12.021</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meunier</surname><given-names>B</given-names></name></person-group><article-title>Hybrid molecules with a dual mode of action: dream or reality</article-title><source>Acc Chem Res</source><year>2008</year><volume>41</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1021/ar7000843</pub-id><?supplied-pmid 17665872?><pub-id pub-id-type="pmid">17665872</pub-id></element-citation></ref><ref id="CR61"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Miessler</surname><given-names>LG</given-names></name><name><surname>Tarr</surname><given-names>AD</given-names></name></person-group><source>Inorganic chemistry</source><year>2004</year><edition>3</edition><publisher-loc>Pearson</publisher-loc><publisher-name>Minnesota</publisher-name></element-citation></ref><ref id="CR62"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Modell</surname><given-names>B</given-names></name><name><surname>Berdoukas</surname><given-names>V</given-names></name></person-group><source>The clinical approach to Thalassemia</source><year>1984</year><publisher-loc>London</publisher-loc><publisher-name>Grune and Stratton</publisher-name></element-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>M</given-names></name></person-group><article-title>Gold complexes as potential anti-parasitic agentes</article-title><source>Coord Chem Rev</source><year>2009</year><volume>253</volume><fpage>1619</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.12.003</pub-id></element-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>H</given-names></name><name><surname>Sanchez-Delgado</surname><given-names>RA</given-names></name></person-group><article-title>Toward a novel metal-based chemotherapy against tropical diseases. 3. Synthesis and antimalarial activity in vitro and in vivo of the new gold-chloroquine complex [Au(PPh<sub>3</sub>)(CQ)]PF<sub>6</sub></article-title><source>J Med Chem</source><year>1997</year><volume>40</volume><fpage>1937</fpage><lpage>1939</lpage><pub-id pub-id-type="doi">10.1021/jm9607358</pub-id><?supplied-pmid 9191972?><pub-id pub-id-type="pmid">9191972</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>V&#x000e1;squez</surname><given-names>F</given-names></name><name><surname>S&#x000e1;nchez-Delgado</surname><given-names>RA</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>H</given-names></name><name><surname>Sinou</surname><given-names>V</given-names></name><name><surname>Schr&#x000e9;vel</surname><given-names>J</given-names></name></person-group><article-title>Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes</article-title><source>J Med Chem</source><year>2004</year><volume>21</volume><fpage>5204</fpage><lpage>5209</lpage><pub-id pub-id-type="doi">10.1021/jm049792o</pub-id></element-citation></ref><ref id="CR66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Gabbiani</surname><given-names>C</given-names></name><name><surname>Messori</surname><given-names>L</given-names></name><name><surname>Gambino</surname><given-names>D</given-names></name></person-group><article-title>Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives</article-title><source>Drug Discovery Today</source><year>2010</year><volume>15</volume><fpage>1070</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2010.10.005</pub-id><?supplied-pmid 20974285?><pub-id pub-id-type="pmid">20974285</pub-id></element-citation></ref><ref id="CR67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Castro</surname><given-names>W</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>A</given-names></name><name><surname>S&#x000e1;nchez Delgado</surname><given-names>RA</given-names></name></person-group><article-title>The mechanism of antimalarial action of [Au(CQ)(PPh)<sub>3</sub>]PF<sub>6</sub>: structural effects and increased drug lipophilicity enhance heme aggregation inhibition at lipid/water interfaces</article-title><source>J Inorg Biochem</source><year>2011</year><volume>105</volume><fpage>276</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2010.11.005</pub-id><?supplied-pmid 21194628?><pub-id pub-id-type="pmid">21194628</pub-id></element-citation></ref><ref id="CR68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nzila</surname><given-names>A</given-names></name></person-group><article-title>The past, present and future of antifolates in the treatment of <italic>Plasmodium falciparum</italic> infection</article-title><source>J Antimicrob Chemother</source><year>2006</year><volume>57</volume><fpage>1043</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1093/jac/dkl104</pub-id><?supplied-pmid 16617066?><pub-id pub-id-type="pmid">16617066</pub-id></element-citation></ref><ref id="CR69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ockenhouse</surname><given-names>CF</given-names></name><name><surname>Magill</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Milhous</surname><given-names>W</given-names></name></person-group><article-title>History of U.S. Military contributions to study of malaria</article-title><source>Mil Med</source><year>2005</year><volume>170</volume><fpage>6</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.7205/MILMED.170.4S.12</pub-id></element-citation></ref><ref id="CR70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pangjit</surname><given-names>K</given-names></name><name><surname>Banjerdpongchai</surname><given-names>R</given-names></name><name><surname>Phisalaphong</surname><given-names>C</given-names></name><name><surname>Fucharoen</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>YY</given-names></name><name><surname>Lu</surname><given-names>ZD</given-names></name><name><surname>Hider</surname><given-names>RC</given-names></name><name><surname>Srichairatanakool</surname><given-names>S</given-names></name></person-group><article-title>Characterisation of a novel oral iron chelator: 1-(N-Acetyl-6-Aminohexyl)-3-Hydroxy-2-Methylpyridin-4-one</article-title><source>J Pharm Pharmacol</source><year>2015</year><volume>67</volume><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1111/jphp.12373</pub-id><?supplied-pmid 25627251?><pub-id pub-id-type="pmid">25627251</pub-id></element-citation></ref><ref id="CR71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponka</surname><given-names>P</given-names></name><name><surname>Richardson</surname><given-names>DR</given-names></name><name><surname>Edward</surname><given-names>JT</given-names></name><name><surname>Chubb</surname><given-names>FL</given-names></name></person-group><article-title>Iron chelators of the pyridoxal isonycotinoyl hydrazone class. Relationship of the lipophilicity of the apo chelator to its ability to mobilize iron from reticulocyte in vitro</article-title><source>Can J Physiol Pharmacol</source><year>1994</year><volume>72</volume><fpage>659</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1139/y94-093</pub-id><?supplied-pmid 7954097?><pub-id pub-id-type="pmid">7954097</pub-id></element-citation></ref><ref id="CR72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prince</surname><given-names>R</given-names></name></person-group><article-title>Artemisinin drugs: novel antimalarial agents</article-title><source>Expert Opin Investig Drugs</source><year>2000</year><volume>9</volume><fpage>1815</fpage><lpage>1827</lpage><pub-id pub-id-type="doi">10.1517/13543784.9.8.1815</pub-id></element-citation></ref><ref id="CR73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quirante</surname><given-names>J</given-names></name><name><surname>Ruiz</surname><given-names>D</given-names></name><name><surname>Gonzalez</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>C</given-names></name><name><surname>Cascante</surname><given-names>M</given-names></name><name><surname>Cort&#x000e9;s</surname><given-names>R</given-names></name><name><surname>Messeguer</surname><given-names>R</given-names></name><name><surname>Calvis</surname><given-names>C</given-names></name><name><surname>Baldoma</surname><given-names>L</given-names></name><name><surname>Pascual</surname><given-names>A</given-names></name><name><surname>Gu&#x000e9;rardel</surname><given-names>Y</given-names></name><name><surname>Pradines</surname><given-names>B</given-names></name><name><surname>Font-Bard&#x000ed;a</surname><given-names>M</given-names></name><name><surname>Calvet</surname><given-names>T</given-names></name><name><surname>Biot</surname><given-names>C</given-names></name></person-group><article-title>Platinum(II) and palladium(II) complexes with (N, N&#x02032;) and (C, N, N&#x02032;) ligands derived from pyrazole as anti-cancer and antimalarial agents: Synthesis, characterization and in vitro activities</article-title><source>J Inorg Biochem</source><year>2011</year><volume>105</volume><fpage>1720</fpage><lpage>1728</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2011.09.021</pub-id><?supplied-pmid 22104300?><pub-id pub-id-type="pmid">22104300</pub-id></element-citation></ref><ref id="CR74"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rabinovitch</surname><given-names>L</given-names></name><name><surname>Silva</surname><given-names>CMB</given-names></name><name><surname>Alves</surname><given-names>RSA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Melo</surname><given-names>IS</given-names></name><name><surname>Azevedo</surname><given-names>JL</given-names></name></person-group><article-title>Controle biol&#x000f3;gico de vetores de doen&#x000e7;as tropicais utilizando Bacillus entomopatog&#x000ea;nicos</article-title><source>Controle biol&#x000f3;gico</source><year>1999</year><publisher-loc>EMBRAPA Meio Ambiente</publisher-loc><publisher-name>Jaguari&#x000fa;na</publisher-name></element-citation></ref><ref id="CR75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>MK</given-names></name><name><surname>Ingle</surname><given-names>AP</given-names></name><name><surname>Paralikar</surname><given-names>P</given-names></name><name><surname>Gupta</surname><given-names>I</given-names></name><name><surname>Medici</surname><given-names>S</given-names></name><name><surname>Santo</surname><given-names>CA</given-names></name></person-group><article-title>Recent Advances in use of silver nanoparticles as antimalarial agents</article-title><source>Int J Pharm</source><year>2017</year><volume>526</volume><fpage>254</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.04.042</pub-id><?supplied-pmid 28450172?><pub-id pub-id-type="pmid">28450172</pub-id></element-citation></ref><ref id="CR03"><mixed-citation publication-type="other">Ridley RG (2002) Medical need, specific opportunity and the drive for antimalarial drugs. Nature 415:686&#x02013;693</mixed-citation></ref><ref id="CR76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>A</given-names></name><name><surname>Benoii-Vical</surname><given-names>F</given-names></name><name><surname>Dechy-Cabaret</surname><given-names>O</given-names></name><etal/></person-group><article-title>From classical antimalarial drugs to new compounds based on the mechanism of action of artemisinin</article-title><source>Pure Appl Chem</source><year>2001</year><volume>73</volume><fpage>1173</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1351/pac200173071173</pub-id></element-citation></ref><ref id="CR77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname><given-names>MNA</given-names></name><name><surname>Ferreira</surname><given-names>EAP</given-names></name><name><surname>Souza</surname><given-names>JM</given-names></name></person-group><article-title>Aspecto hist&#x000f3;rico da mal&#x000e1;ria</article-title><source>Revista Paraense de Medicina</source><year>2006</year><volume>20</volume><issue>3</issue><fpage>81</fpage><lpage>82</lpage></element-citation></ref><ref id="CR78"><mixed-citation publication-type="other">Russel PF (1968) The United States and malaria: debits and credits. Bulletin of the New York Academy of Medicine. 44:623
</mixed-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salas</surname><given-names>FP</given-names></name><name><surname>Herrmann</surname><given-names>C</given-names></name><name><surname>Orvig</surname><given-names>C</given-names></name></person-group><article-title>Metalloantimalarials</article-title><source>Chem Rev</source><year>2013</year><volume>113</volume><fpage>3450</fpage><lpage>3492</lpage><pub-id pub-id-type="doi">10.1021/cr3001252</pub-id><?supplied-pmid 23425067?><pub-id pub-id-type="pmid">23425067</pub-id></element-citation></ref><ref id="CR80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Delgado</surname><given-names>R</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Perez</surname><given-names>H</given-names></name><name><surname>Urbina</surname><given-names>JA</given-names></name></person-group><article-title>Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium and rhodium-chloroquine complexes</article-title><source>J Med Chem</source><year>1996</year><volume>39</volume><fpage>1095</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1021/jm950729w</pub-id><?supplied-pmid 8676344?><pub-id pub-id-type="pmid">8676344</pub-id></element-citation></ref><ref id="CR81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheibel</surname><given-names>LW</given-names></name><name><surname>Rodriguez</surname><given-names>S</given-names></name></person-group><article-title>Anti-malarial activity of selected aromatic chelators. V. Localization of 59Fe in <italic>Plasmodium falciparum</italic> in the presence of oxines</article-title><source>Prog Clin Biol Res</source><year>1989</year><volume>313</volume><fpage>119</fpage><lpage>149</lpage><?supplied-pmid 2506579?><pub-id pub-id-type="pmid">2506579</pub-id></element-citation></ref><ref id="CR82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seuanes</surname><given-names>GC</given-names></name><name><surname>Moreira</surname><given-names>MB</given-names></name><name><surname>Petta</surname><given-names>T</given-names></name><name><surname>Moraes</surname><given-names>DMPF</given-names></name><name><surname>Moraes</surname><given-names>LAB</given-names></name><name><surname>Oliveira</surname><given-names>ARM</given-names></name><name><surname>Naal</surname><given-names>GZMR</given-names></name><name><surname>Nikolaou</surname><given-names>S</given-names></name></person-group><article-title>Novel binuclear &#x003bc;-oxo diruthenium complexes combined with ibuprofen and ketoprofen: interaction with relevant target biomolecules and anti-allergic potential</article-title><source>J Inorg Biochem</source><year>2015</year><volume>153</volume><fpage>178</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2015.08.004</pub-id><?supplied-pmid 26298864?><pub-id pub-id-type="pmid">26298864</pub-id></element-citation></ref><ref id="CR83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>V</given-names></name></person-group><article-title>Therapeutic drugs for targeting chloroquine resistance in malaria</article-title><source>Mini-Rev Med Chem</source><year>2005</year><volume>5</volume><fpage>337</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.2174/1389557053544029</pub-id><?supplied-pmid 15853624?><pub-id pub-id-type="pmid">15853624</pub-id></element-citation></ref><ref id="CR84"><mixed-citation publication-type="other">Sibley CH, Ringwald PA (2007) Database of antimalarial drug resistance. In http:<ext-link ext-link-type="uri" xlink:href="http://www.malariajournal.com/">www.malariajournal.com/</ext-link> content/5/1/48</mixed-citation></ref><ref id="CR85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>THA</given-names></name><name><surname>Oliveira</surname><given-names>MT</given-names></name><name><surname>dos Santos</surname><given-names>HF</given-names></name><name><surname>de Oliveira</surname><given-names>AB</given-names></name><name><surname>de Almeida</surname><given-names>WB</given-names></name></person-group><article-title>Estudo de modelagem molecular de complexos ferriprotoporfirina-IX e quinolinocarbinolaminas antimal&#x000e1;ricos: Proposta de um farmac&#x000f3;foro</article-title><source>Quim Nova</source><year>2005</year><volume>28</volume><fpage>244</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1590/S0100-40422005000200015</pub-id></element-citation></ref><ref id="CR86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>BN</given-names></name><name><surname>Carmo</surname><given-names>LMA</given-names></name><name><surname>Lagatta</surname><given-names>CD</given-names></name><name><surname>Alves</surname><given-names>MJM</given-names></name><name><surname>Fontes</surname><given-names>SPA</given-names></name><name><surname>Coimbra</surname><given-names>SE</given-names></name><name><surname>Silva</surname><given-names>DA</given-names></name><name><surname>Abramo</surname><given-names>C</given-names></name></person-group><article-title>4-aminoquinoline analogues and its platinum (II) complexes as antimalarials agents</article-title><source>Biomed Pharmacother</source><year>2011</year><volume>65</volume><fpage>313</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2011.03.003</pub-id><?supplied-pmid 21704476?><pub-id pub-id-type="pmid">21704476</pub-id></element-citation></ref><ref id="CR87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapanelli</surname><given-names>S</given-names></name><name><surname>Habluetzel</surname><given-names>A</given-names></name><name><surname>Pellei</surname><given-names>M</given-names></name><name><surname>Marchi&#x000f3;</surname><given-names>L</given-names></name><name><surname>Tombesi</surname><given-names>A</given-names></name><name><surname>Cappar&#x000e9;</surname><given-names>A</given-names></name><name><surname>Santini</surname><given-names>A</given-names></name></person-group><article-title>Novel metalloantimalarials: Transmission blocking effects of water soluble Cu (I), Ag(I) and Au(I) phosphane complexes on the murine malaria parasite <italic>Plasmodium berghei</italic></article-title><source>J Inorg Biochem</source><year>2017</year><volume>166</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2016.10.004</pub-id><?supplied-pmid 27815977?><pub-id pub-id-type="pmid">27815977</pub-id></element-citation></ref><ref id="CR88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Schalkuyk</surname><given-names>DA</given-names></name><name><surname>Walder</surname><given-names>JC</given-names></name><name><surname>Smith</surname><given-names>PJ</given-names></name></person-group><article-title>Reversal of chloroquine resistance in <italic>Plasmodium falciparum</italic> using combinations of chemosensitizers</article-title><source>Antimicrob Agents Chemotherapy</source><year>2001</year><volume>45</volume><fpage>593</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1128/AAC.45.2.593-595.2001</pub-id></element-citation></ref><ref id="CR89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van-Staveren</surname><given-names>DR</given-names></name><name><surname>Metzler-Nolte</surname><given-names>N</given-names></name></person-group><article-title>Bioorganometallic chemistry of ferrocene</article-title><source>Chem Rev</source><year>2004</year><volume>104</volume><fpage>5931</fpage><lpage>5986</lpage><pub-id pub-id-type="doi">10.1021/cr0101510</pub-id><?supplied-pmid 15584693?><pub-id pub-id-type="pmid">15584693</pub-id></element-citation></ref><ref id="CR90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieites</surname><given-names>M</given-names></name><name><surname>Smircich</surname><given-names>P</given-names></name><name><surname>Guggeri</surname><given-names>L</given-names></name><name><surname>March&#x000e1;n</surname><given-names>E</given-names></name><name><surname>G&#x000f3;nrez-Barrio</surname><given-names>A</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Garat</surname><given-names>B</given-names></name><name><surname>Gambino</surname><given-names>D</given-names></name></person-group><article-title>Synthesis and characteization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproferative effect against <italic>Trypanosoma cruzi</italic> and <italic>Leishmania</italic> sp insight into its mechanism of action</article-title><source>J Inorg Biochem</source><year>2009</year><volume>103</volume><fpage>1300</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2009.02.011</pub-id><?supplied-pmid 19361864?><pub-id pub-id-type="pmid">19361864</pub-id></element-citation></ref><ref id="CR01"><mixed-citation publication-type="other">Wallace DJ (1989) The use of quinacrine (atrabine) in rheumatic diseases: a reexamination. Semin Arthritis Rheu 18:282&#x02013;297</mixed-citation></ref><ref id="CR91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wani</surname><given-names>AW</given-names></name><name><surname>Jameel</surname><given-names>E</given-names></name><name><surname>Baig</surname><given-names>U</given-names></name><name><surname>Mumtazuddin</surname><given-names>S</given-names></name><name><surname>Hun</surname><given-names>TL</given-names></name></person-group><article-title>Ferroquine and its derivatives: new generation of antimalarial agents</article-title><source>Eur J Med Chem</source><year>2015</year><volume>01</volume><fpage>534</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2015.07.009</pub-id></element-citation></ref><ref id="CR92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasi</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>HB</given-names></name><name><surname>Gajanana</surname><given-names>A</given-names></name><name><surname>Raichowdhary</surname><given-names>AN</given-names></name></person-group><article-title>Synthesis of metal complexes of antimalarial drugs and in vitro evaluation of their activity against <italic>Plasmodium falciparum</italic></article-title><source>Original Inorg Chimica Acta</source><year>1987</year><volume>135</volume><fpage>133</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/S0020-1693(00)83277-6</pub-id></element-citation></ref><ref id="CR94"><mixed-citation publication-type="other">WHO (2017) <ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/en/">http://www.who.int/malaria/en/</ext-link></mixed-citation></ref><ref id="CR95"><mixed-citation publication-type="other">WHO Facts on ACTs (Artemisinin-based Combination Therapies) (2007) In:<ext-link ext-link-type="uri" xlink:href="http://rbm.who.int/cmc_upload/">http://rbm.who.int/cmc_upload/</ext-link> 0/000/015/364/RBMInfosheet_9.htm</mixed-citation></ref><ref id="CR97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yalcindag</surname><given-names>E</given-names></name><name><surname>Elguero</surname><given-names>E</given-names></name><name><surname>Arnathau</surname><given-names>C</given-names></name><name><surname>Durand</surname><given-names>P</given-names></name><name><surname>Akiana</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Aubouy</surname><given-names>A</given-names></name><name><surname>Balloux</surname><given-names>F</given-names></name><name><surname>Besnard</surname><given-names>P</given-names></name><name><surname>Bogreau</surname><given-names>H</given-names></name><name><surname>Carnevale</surname><given-names>P</given-names></name><name><surname>D&#x02019;Alessandro</surname><given-names>U</given-names></name><name><surname>Fontenille</surname><given-names>Gamboa D</given-names></name><name><surname>Jombart</surname><given-names>T</given-names></name><name><surname>Le Mire</surname><given-names>J</given-names></name><name><surname>Leroy</surname><given-names>E</given-names></name><name><surname>Maestre</surname><given-names>A</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>M&#x000e9;nard</surname><given-names>D</given-names></name><name><surname>Musset</surname><given-names>L</given-names></name><name><surname>Newton</surname><given-names>PN</given-names></name><name><surname>Nkogh&#x000e9;</surname><given-names>D</given-names></name><name><surname>Noya</surname><given-names>O</given-names></name><name><surname>Ollomo</surname><given-names>B</given-names></name><name><surname>Rogier</surname><given-names>C</given-names></name><name><surname>Veron</surname><given-names>V</given-names></name><name><surname>Wide</surname><given-names>A</given-names></name><name><surname>Zakeri</surname><given-names>S</given-names></name><name><surname>Carme</surname><given-names>B</given-names></name><name><surname>Legrand</surname><given-names>E</given-names></name><name><surname>Chevillon</surname><given-names>C</given-names></name><name><surname>Ayala</surname><given-names>FJ</given-names></name><name><surname>Renaud</surname><given-names>F</given-names></name><name><surname>Prugnolle</surname><given-names>F</given-names></name></person-group><article-title>Multiple independent introductions of <italic>Plasmodium falciparum</italic> in South America</article-title><source>Proc Nat Acad Sci</source><year>2012</year><volume>109</volume><fpage>511</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1073/pnas.1119058109</pub-id><?supplied-pmid 22203975?><pub-id pub-id-type="pmid">22203975</pub-id></element-citation></ref><ref id="CR98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Lai</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>B</given-names></name><name><surname>Wan</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Synthesis characterization in vitro cytotoxicity and anticancer affects of ruthenium(II) complexes on BEL-7402 cells</article-title><source>J Inorg Biochem</source><year>2016</year><volume>157</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2016.01.003</pub-id><?supplied-pmid 26828285?><pub-id pub-id-type="pmid">26828285</pub-id></element-citation></ref></ref-list></back></article>